Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative...
Saved in:
| Published in | The Lancet (British edition) Vol. 382; no. 9896; pp. 951 - 962 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier Ltd
14.09.2013
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs.
We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation.
We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73–1·03; amisulpride 0·66, 0·53–0·78; olanzapine 0·59, 0·53–0·65; risperidone 0·56, 0·50–0·63; paliperidone 0·50, 0·39–0·60; zotepine 0·49, 0·31–0·66; haloperidol 0·45, 0·39–0·51; quetiapine 0·44, 0·35–0·52; aripiprazole 0·43, 0·34–0·52; sertindole 0·39, 0·26–0·52; ziprasidone 0·39, 0·30–0·49; chlorpromazine 0·38, 0·23–0·54; asenapine 0·38, 0·25–0·51; lurasidone 0·33, 0·21–0·45; and iloperidone 0·33, 0·22–0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from −0·09 for the best drug (haloperidol) to −0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to −1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to −0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses.
Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines.
None. |
|---|---|
| AbstractList | Background The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs. Methods We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation. Findings We identified 212 suitable trials, with data for 43049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0 times 88, 0 times 73-1 times 03; amisulpride 0 times 66, 0 times 53-0 times 78; olanzapine 0 times 59, 0 times 53-0 times 65; risperidone 0 times 56, 0 times 50-0 times 63; paliperidone 0 times 50, 0 times 39-0 times 60; zotepine 0 times 49, 0 times 31-0 times 66; haloperidol 0 times 45, 0 times 39-0 times 51; quetiapine 0 times 44, 0 times 35-0 times 52; aripiprazole 0 times 43, 0 times 34-0 times 52; sertindole 0 times 39, 0 times 26-0 times 52; ziprasidone 0 times 39, 0 times 30-0 times 49; chlorpromazine 0 times 38, 0 times 23-0 times 54; asenapine 0 times 38, 0 times 25-0 times 51; lurasidone 0 times 33, 0 times 21-0 times 45; and iloperidone 0 times 33, 0 times 22-0 times 43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0 times 43 for the best drug (amisulpride) to 0 times 80 for the worst drug (haloperidol); for extrapyramidal side-effects 0 times 30 (clozapine) to 4 times 76 (haloperidol); and for sedation 1 times 42 (amisulpride) to 8 times 82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from -0 times 09 for the best drug (haloperidol) to -0 times 74 for the worst drug (olanzapine), for prolactin increase 0 times 22 (aripiprazole) to -1 times 30 (paliperidone), and for QTc prolongation 0 times 10 (lurasidone) to -0 times 90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses. Interpretation Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines. Funding None. Background: The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs. Methods: We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation. Findings: We identified 212 suitable trials, with data for 43[puncsp]049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0.88, 0.73-1.03; amisulpride 0.66, 0.53-0.78; olanzapine 0.59, 0.53-0.65; risperidone 0.56, 0.50-0.63; paliperidone 0.50, 0.39-0.60; zotepine 0.49, 0.31-0.66; haloperidol 0.45, 0.39-0.51; quetiapine 0.44, 0.35-0.52; aripiprazole 0.43, 0.34-0.52; sertindole 0.39, 0.26-0.52; ziprasidone 0.39, 0.30-0.49; chlorpromazine 0.38, 0.23-0.54; asenapine 0.38, 0.25-0.51; lurasidone 0.33, 0.21-0.45; and iloperidone 0.33, 0.22-0.43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0.43 for the best drug (amisulpride) to 0.80 for the worst drug (haloperidol); for extrapyramidal side-effects 0.30 (clozapine) to 4.76 (haloperidol); and for sedation 1.42 (amisulpride) to 8.82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from -0.09 for the best drug (haloperidol) to -0.74 for the worst drug (olanzapine), for prolactin increase 0.22 (aripiprazole) to -1.30 (paliperidone), and for QTc prolongation 0.10 (lurasidone) to -0.90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses. Interpretation: Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines. Funding None. The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs. We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation. We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73–1·03; amisulpride 0·66, 0·53–0·78; olanzapine 0·59, 0·53–0·65; risperidone 0·56, 0·50–0·63; paliperidone 0·50, 0·39–0·60; zotepine 0·49, 0·31–0·66; haloperidol 0·45, 0·39–0·51; quetiapine 0·44, 0·35–0·52; aripiprazole 0·43, 0·34–0·52; sertindole 0·39, 0·26–0·52; ziprasidone 0·39, 0·30–0·49; chlorpromazine 0·38, 0·23–0·54; asenapine 0·38, 0·25–0·51; lurasidone 0·33, 0·21–0·45; and iloperidone 0·33, 0·22–0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from −0·09 for the best drug (haloperidol) to −0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to −1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to −0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses. Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines. None. Summary Background The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs. Methods We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation. Findings We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73–1·03; amisulpride 0·66, 0·53–0·78; olanzapine 0·59, 0·53–0·65; risperidone 0·56, 0·50–0·63; paliperidone 0·50, 0·39–0·60; zotepine 0·49, 0·31–0·66; haloperidol 0·45, 0·39–0·51; quetiapine 0·44, 0·35–0·52; aripiprazole 0·43, 0·34–0·52; sertindole 0·39, 0·26–0·52; ziprasidone 0·39, 0·30–0·49; chlorpromazine 0·38, 0·23–0·54; asenapine 0·38, 0·25–0·51; lurasidone 0·33, 0·21–0·45; and iloperidone 0·33, 0·22–0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from −0·09 for the best drug (haloperidol) to −0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to −1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to −0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses. Interpretation Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines. Funding None. The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs. Methods: We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, andClinicalTrials.govfor reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation. Findings: We identified 212 suitable trials, with data for 43?049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0· ;38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0· ;33, 0·22-0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8· ;82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from ?0·09 for the best drug (haloperidol) to ?0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to ?1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to ?0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses. Interpretation: Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines. 60 references The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs.BACKGROUNDThe question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs.We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation.METHODSWe did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation.We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from -0·09 for the best drug (haloperidol) to -0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to -1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to -0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses.FINDINGSWe identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from -0·09 for the best drug (haloperidol) to -0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to -1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to -0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses.Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines.INTERPRETATIONAntipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines.None.FUNDINGNone. BACKGROUND: The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs. METHODS: We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation. FINDINGS: We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73–1·03; amisulpride 0·66, 0·53–0·78; olanzapine 0·59, 0·53–0·65; risperidone 0·56, 0·50–0·63; paliperidone 0·50, 0·39–0·60; zotepine 0·49, 0·31–0·66; haloperidol 0·45, 0·39–0·51; quetiapine 0·44, 0·35–0·52; aripiprazole 0·43, 0·34–0·52; sertindole 0·39, 0·26–0·52; ziprasidone 0·39, 0·30–0·49; chlorpromazine 0·38, 0·23–0·54; asenapine 0·38, 0·25–0·51; lurasidone 0·33, 0·21–0·45; and iloperidone 0·33, 0·22–0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from −0·09 for the best drug (haloperidol) to −0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to −1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to −0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses. INTERPRETATION: Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines. FUNDING: None. The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs. We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation. We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from -0·09 for the best drug (haloperidol) to -0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to -1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to -0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses. Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines. None. The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs. Methods We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, andClinicalTrials.govfor reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation. Findings We identified 212 suitable trials, with data for 43?049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from ?0·09 for the best drug (haloperidol) to ?0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to ?1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to ?0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses. Interpretation Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines. Funding None. |
| Author | Barbui, Corrado Spineli, Loukia Salanti, Georgia Leucht, Stefan Geddes, John R Mavridis, Dimitris Lässig, Bettina Örey, Deniz Samara, Myrto Cipriani, Andrea Stapf, Marko Paul Richter, Franziska Engel, Rolf R Kissling, Werner Davis, John M |
| Author_xml | – sequence: 1 givenname: Stefan surname: Leucht fullname: Leucht, Stefan email: stefan.leucht@lrz.tum.de organization: Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Munich, Germany – sequence: 2 givenname: Andrea surname: Cipriani fullname: Cipriani, Andrea organization: Department of Medicine and Public Health, Section of Psychiatry, University of Verona, Verona, Italy – sequence: 3 givenname: Loukia surname: Spineli fullname: Spineli, Loukia organization: Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece – sequence: 4 givenname: Dimitris surname: Mavridis fullname: Mavridis, Dimitris organization: Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece – sequence: 5 givenname: Deniz surname: Örey fullname: Örey, Deniz organization: Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Munich, Germany – sequence: 6 givenname: Franziska surname: Richter fullname: Richter, Franziska organization: Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Munich, Germany – sequence: 7 givenname: Myrto surname: Samara fullname: Samara, Myrto organization: Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Munich, Germany – sequence: 8 givenname: Corrado surname: Barbui fullname: Barbui, Corrado organization: Department of Medicine and Public Health, Section of Psychiatry, University of Verona, Verona, Italy – sequence: 9 givenname: Rolf R surname: Engel fullname: Engel, Rolf R organization: Psychiatrische Klinik der Ludwig-Maximilian–Universität München, Munich, Germany – sequence: 10 givenname: John R surname: Geddes fullname: Geddes, John R organization: Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK – sequence: 11 givenname: Werner surname: Kissling fullname: Kissling, Werner organization: Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Munich, Germany – sequence: 12 givenname: Marko Paul surname: Stapf fullname: Stapf, Marko Paul organization: Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Munich, Germany – sequence: 13 givenname: Bettina surname: Lässig fullname: Lässig, Bettina organization: Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Munich, Germany – sequence: 14 givenname: Georgia surname: Salanti fullname: Salanti, Georgia organization: Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece – sequence: 15 givenname: John M surname: Davis fullname: Davis, John M organization: Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, USA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27674696$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23810019$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk11rFDEUhgep2G31J6gDItSL0WTyMZmKiix-QcGLWvAuZDJnuqkzyZpkCuOvN_tRCwuyexU4PO97Tk7enGRH1lnIsqcYvcYI8zeXCFNU8IrwM0xecVQRUpAH2QzTihaMVj-Pstk_5Dg7CeEGIUQ5Yo-y45IIjBCuZ9k4d8NSeRXNLeTQdUYrPeXKtnl0PXjVmN7EKXddjlkqR7MMk164aHTe-vE65MbmQS_MH7dceLBGnecqH8Y-gT0U0YOKA9gY8gGiKpRV_RRMeJw97FQf4Mn2PM2uPn_6Mf9aXHz_8m3-8aLQFaOxYJxx3YiacFzVvOKEI0BlgxXltOMNUQTalhMqagDcpFLb6ZqrWtSl6BhryGl2tvFdevd7hBDlYIKGvlcW3Bgk5pVgRHDMDkC5KKkgGO9HKeeoxnWi96NUlJhVgh6AElLymrEV-mIHvXGjT7tdU8lP4PWNnm2psRmglUtvBuUneff4CXi5BVTQqu-8stqEe67iFeU1T9zbDae9C8FDJ7WJKTHORq9MLzGSq0jKdSTlKm8SE7mOpCRJzXbUdw326Z5vdJ1yUl37NNnVZYkwS7MTRNhquR82BKQI3RrwMmgDVkNrPOgoW2f29ni_46B7Y9Mf6H_BBOF-qzKUEm1MVh6YrB1WBu_-b3DAAH8BNwomoA |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1016_j_neuron_2015_10_047 crossref_primary_10_1016_j_ijcard_2024_131788 crossref_primary_10_3892_mmr_2025_13479 crossref_primary_10_1016_j_euroneuro_2015_07_008 crossref_primary_10_1016_j_rpsm_2014_05_004 crossref_primary_10_1177_2045125316632458 crossref_primary_10_3390_neurolint13040062 crossref_primary_10_1186_s12888_022_03910_6 crossref_primary_10_1017_ipm_2021_4 crossref_primary_10_1097_YIC_0000000000000564 crossref_primary_10_1371_journal_pone_0246211 crossref_primary_10_1177_070674371506000503 crossref_primary_10_3390_molecules29050964 crossref_primary_10_1177_070674371506000502 crossref_primary_10_1016_S0140_6736_13_62615_X crossref_primary_10_1192_bja_2019_49 crossref_primary_10_1016_j_psychres_2020_112851 crossref_primary_10_9740_mhc_2022_08_254 crossref_primary_10_12968_bjmh_2015_4_2_50 crossref_primary_10_9758_cpn_2016_14_4_371 crossref_primary_10_1016_j_euroneuro_2016_02_002 crossref_primary_10_1016_j_jpsychires_2018_08_002 crossref_primary_10_1177_0706743716661324 crossref_primary_10_1080_14656566_2019_1617849 crossref_primary_10_1007_s11845_024_03806_2 crossref_primary_10_1016_j_enfcli_2019_09_023 crossref_primary_10_1080_14740338_2017_1288716 crossref_primary_10_1080_14740338_2016_1201475 crossref_primary_10_1007_s11920_013_0433_9 crossref_primary_10_1016_j_neuroscience_2016_08_055 crossref_primary_10_1097_WNF_0000000000000134 crossref_primary_10_1176_appi_ajp_2015_15030332 crossref_primary_10_1016_j_scog_2021_100204 crossref_primary_10_1177_20451253221113238 crossref_primary_10_1097_WNF_0000000000000117 crossref_primary_10_1007_s00406_018_0880_8 crossref_primary_10_1038_s41386_019_0440_6 crossref_primary_10_1016_j_neubiorev_2022_104979 crossref_primary_10_1016_j_ejphar_2016_01_009 crossref_primary_10_1097_JCP_0000000000001158 crossref_primary_10_1002_mdc3_12812 crossref_primary_10_1016_j_mehy_2024_111361 crossref_primary_10_1002_psp4_12488 crossref_primary_10_1016_j_psychres_2016_05_039 crossref_primary_10_1080_13696998_2017_1351370 crossref_primary_10_3389_fphar_2023_1215065 crossref_primary_10_1016_j_schres_2013_11_009 crossref_primary_10_1002_14651858_CD012807_pub2 crossref_primary_10_1136_bmjopen_2021_048619 crossref_primary_10_30629_2618_6667_2024_22_5_12_21 crossref_primary_10_3928_00485713_20150401_09 crossref_primary_10_1017_S1092852920001376 crossref_primary_10_1016_j_jamda_2014_10_010 crossref_primary_10_1177_0269881119889296 crossref_primary_10_1016_j_schres_2018_05_009 crossref_primary_10_1017_S109285291900124X crossref_primary_10_1517_14656566_2014_956082 crossref_primary_10_1080_14737175_2022_2060742 crossref_primary_10_1371_journal_pone_0201371 crossref_primary_10_1007_s40264_016_0436_7 crossref_primary_10_1007_s10578_022_01330_x crossref_primary_10_1016_j_ijmedinf_2024_105483 crossref_primary_10_2196_69359 crossref_primary_10_1021_acschemneuro_7b00087 crossref_primary_10_1093_schbul_sbx072 crossref_primary_10_1097_JCP_0000000000001131 crossref_primary_10_1016_j_euroneuro_2018_05_016 crossref_primary_10_1007_s12264_021_00740_6 crossref_primary_10_1016_S0140_6736_14_60379_2 crossref_primary_10_1177_0269881114560184 crossref_primary_10_1111_appy_12207 crossref_primary_10_1517_14656566_2015_1032248 crossref_primary_10_1007_s43440_025_00713_w crossref_primary_10_2147_NDT_S324145 crossref_primary_10_1002_brb3_2109 crossref_primary_10_1017_S2045796020000232 crossref_primary_10_1016_j_schres_2023_09_036 crossref_primary_10_1055_a_2437_4366 crossref_primary_10_1002_14651858_CD012452 crossref_primary_10_1177_2045125317693200 crossref_primary_10_1177_2050313X211004796 crossref_primary_10_1097_JCP_0000000000001585 crossref_primary_10_1177_1049731515622687 crossref_primary_10_1016_j_mpmed_2016_08_003 crossref_primary_10_1124_pr_113_008219 crossref_primary_10_1016_j_mcna_2024_09_002 crossref_primary_10_1016_j_jpsychires_2025_02_019 crossref_primary_10_4236_pp_2015_68042 crossref_primary_10_1016_j_jpsychires_2016_12_021 crossref_primary_10_3389_fpsyt_2022_737295 crossref_primary_10_1017_S0033291714001214 crossref_primary_10_1038_s41598_021_87285_w crossref_primary_10_1016_j_schres_2015_09_019 crossref_primary_10_1176_appi_ajp_2015_15111466 crossref_primary_10_1039_C8TX00261D crossref_primary_10_1007_s15202_017_1494_0 crossref_primary_10_3390_ijerph191710844 crossref_primary_10_1248_yakushi_23_00105 crossref_primary_10_1080_14737175_2016_1174577 crossref_primary_10_1097_JCP_0000000000001594 crossref_primary_10_3310_HLZE0479 crossref_primary_10_1016_j_taap_2020_115214 crossref_primary_10_1007_s40265_018_0874_x crossref_primary_10_1007_s00406_018_0897_z crossref_primary_10_1016_j_bcp_2024_116020 crossref_primary_10_2147_IJGM_S320611 crossref_primary_10_1093_ijnp_pyad029 crossref_primary_10_1007_s11920_014_0529_x crossref_primary_10_1016_j_schres_2016_04_013 crossref_primary_10_1016_j_schres_2016_04_012 crossref_primary_10_1007_s11920_015_0550_8 crossref_primary_10_1016_j_jpsychires_2019_01_006 crossref_primary_10_3389_fpsyt_2020_00600 crossref_primary_10_2196_22631 crossref_primary_10_1016_j_canlet_2018_01_058 crossref_primary_10_36290_far_2017_016 crossref_primary_10_1016_j_jacl_2015_08_002 crossref_primary_10_4306_jknpa_2018_57_4_301 crossref_primary_10_1016_S2215_0366_19_30088_4 crossref_primary_10_1016_j_jad_2021_09_109 crossref_primary_10_1097_WNF_0000000000000181 crossref_primary_10_3389_fnut_2021_815456 crossref_primary_10_1007_s00213_016_4324_8 crossref_primary_10_1016_j_biopsych_2023_10_023 crossref_primary_10_1038_s41467_018_04711_w crossref_primary_10_1007_s40263_017_0461_9 crossref_primary_10_3389_fpsyt_2020_00613 crossref_primary_10_1111_eip_12683 crossref_primary_10_1016_j_bbi_2020_06_017 crossref_primary_10_1016_j_cpha_2022_09_003 crossref_primary_10_1007_s40263_016_0382_z crossref_primary_10_1016_j_schres_2021_04_009 crossref_primary_10_31363_2313_7053_2023_893 crossref_primary_10_1002_brb3_1211 crossref_primary_10_1017_S1092852913000904 crossref_primary_10_3389_fpsyt_2022_815718 crossref_primary_10_1007_s40261_021_01094_7 crossref_primary_10_3371_CSRP_MCCI_010316 crossref_primary_10_1002_wps_20632 crossref_primary_10_4306_pi_2015_12_1_46 crossref_primary_10_1007_s00228_016_2194_y crossref_primary_10_1080_14740338_2020_1713091 crossref_primary_10_1016_S2215_0366_18_30252_9 crossref_primary_10_1186_s12991_020_00321_3 crossref_primary_10_1007_s11845_021_02576_5 crossref_primary_10_1080_17512433_2018_1445968 crossref_primary_10_1055_a_2299_0927 crossref_primary_10_2174_1389557520666200910092327 crossref_primary_10_1111_ijcp_12714 crossref_primary_10_1002_14651858_CD012429 crossref_primary_10_1080_17512433_2019_1617695 crossref_primary_10_3389_fpsyg_2019_02306 crossref_primary_10_1093_aje_kwae029 crossref_primary_10_1177_0269881116654697 crossref_primary_10_1111_eip_12225 crossref_primary_10_1016_j_schres_2018_12_006 crossref_primary_10_1080_03007995_2018_1513834 crossref_primary_10_1177_0272989X19835239 crossref_primary_10_3389_fgene_2020_00350 crossref_primary_10_1371_journal_pone_0163796 crossref_primary_10_1016_j_metabol_2022_155335 crossref_primary_10_1177_0269881114568042 crossref_primary_10_1177_2045125315614739 crossref_primary_10_3310_hsdr09100 crossref_primary_10_1111_eip_12230 crossref_primary_10_3390_brainsci13050822 crossref_primary_10_1016_j_euroneuro_2016_11_012 crossref_primary_10_3389_fpsyt_2018_00781 crossref_primary_10_1016_j_euroneuro_2021_02_009 crossref_primary_10_1038_s41398_021_01778_w crossref_primary_10_1016_j_bbr_2022_114276 crossref_primary_10_1111_eip_12246 crossref_primary_10_3390_ph13120457 crossref_primary_10_21518_2079_701X_2021_19_109_118 crossref_primary_10_1002_wps_20204 crossref_primary_10_1055_a_0801_2103 crossref_primary_10_1016_j_jpsychires_2024_07_028 crossref_primary_10_1016_j_pnpbp_2014_11_006 crossref_primary_10_1186_s12888_020_03034_9 crossref_primary_10_1017_S109285291300093X crossref_primary_10_1016_j_psc_2015_05_001 crossref_primary_10_3389_fnbeh_2015_00131 crossref_primary_10_1097_WNF_0000000000000170 crossref_primary_10_1111_dom_13522 crossref_primary_10_1111_bcpt_13580 crossref_primary_10_1111_eip_12251 crossref_primary_10_1016_j_schres_2021_02_004 crossref_primary_10_1186_s12888_015_0559_x crossref_primary_10_1055_a_2110_4259 crossref_primary_10_1097_JCP_0000000000001188 crossref_primary_10_1136_bmjopen_2017_017406 crossref_primary_10_1055_s_0034_1370281 crossref_primary_10_1177_0706743717752916 crossref_primary_10_1016_j_neuron_2019_05_013 crossref_primary_10_1007_s00228_020_02830_2 crossref_primary_10_2174_1570159X21666230224102318 crossref_primary_10_1586_17512433_2015_1040393 crossref_primary_10_1159_000486966 crossref_primary_10_1186_s12888_017_1425_9 crossref_primary_10_3389_fpsyt_2024_1497565 crossref_primary_10_1016_j_bbr_2019_112315 crossref_primary_10_1097_FAD_0000000000000034 crossref_primary_10_3389_fpsyt_2021_653642 crossref_primary_10_1155_2020_6352175 crossref_primary_10_1038_s41537_018_0053_9 crossref_primary_10_1097_FTD_0000000000000513 crossref_primary_10_1016_j_ajp_2024_104202 crossref_primary_10_1093_schbul_sbac001 crossref_primary_10_3389_fpsyt_2018_00690 crossref_primary_10_1016_j_nicl_2023_103515 crossref_primary_10_1186_s12991_017_0159_x crossref_primary_10_1007_s10072_022_06360_w crossref_primary_10_3389_fpsyt_2024_1400621 crossref_primary_10_1111_acps_12677 crossref_primary_10_1124_jpet_120_000164 crossref_primary_10_3390_ijms18030568 crossref_primary_10_3390_ijms24076492 crossref_primary_10_3389_fphar_2025_1550015 crossref_primary_10_1177_2054270418758570 crossref_primary_10_1080_08039488_2019_1622152 crossref_primary_10_1007_s40263_020_00718_4 crossref_primary_10_1016_j_rpsm_2021_01_004 crossref_primary_10_1016_j_schres_2017_01_046 crossref_primary_10_1016_j_ejim_2018_02_030 crossref_primary_10_1007_s11154_019_09503_1 crossref_primary_10_1016_j_euroneuro_2018_09_007 crossref_primary_10_1016_j_rpsm_2015_11_003 crossref_primary_10_9740_mhc_2023_08_196 crossref_primary_10_1016_j_euroneuro_2015_12_035 crossref_primary_10_1192_bjp_2023_21 crossref_primary_10_1089_scd_2019_0265 crossref_primary_10_1517_13543784_2016_1121995 crossref_primary_10_2217_pgs_2020_0115 crossref_primary_10_1111_bph_16507 crossref_primary_10_1007_s00406_022_01393_w crossref_primary_10_1016_j_neubiorev_2024_105968 crossref_primary_10_1186_s13063_016_1245_0 crossref_primary_10_1097_YIC_0000000000000095 crossref_primary_10_1097_YIC_0000000000000092 crossref_primary_10_22391_920_256689 crossref_primary_10_1097_JCP_0000000000000614 crossref_primary_10_1097_YIC_0000000000000091 crossref_primary_10_1007_s00213_017_4784_5 crossref_primary_10_3389_fnbeh_2015_00210 crossref_primary_10_1155_2018_9516592 crossref_primary_10_3390_pharmacy11050162 crossref_primary_10_1038_s41386_020_0703_2 crossref_primary_10_1186_s12888_018_1714_y crossref_primary_10_1007_s00228_018_2498_1 crossref_primary_10_1017_S1092852919000865 crossref_primary_10_1016_j_ejmech_2014_12_045 crossref_primary_10_1159_000437430 crossref_primary_10_1007_s40263_014_0157_3 crossref_primary_10_1007_s00429_014_0911_9 crossref_primary_10_1016_j_euroneuro_2014_08_003 crossref_primary_10_1192_bjpo_bp_115_001248 crossref_primary_10_1016_j_bmc_2016_10_010 crossref_primary_10_5649_jjphcs_42_174 crossref_primary_10_1523_ENEURO_0362_24_2024 crossref_primary_10_1177_0269881119885260 crossref_primary_10_1016_j_jpsychires_2017_02_009 crossref_primary_10_1517_14656566_2015_1013029 crossref_primary_10_1097_JCP_0000000000001924 crossref_primary_10_1016_S2215_0366_16_00023_7 crossref_primary_10_4306_pi_2016_13_4_413 crossref_primary_10_1097_JCP_0000000000001921 crossref_primary_10_1017_S1041610220004172 crossref_primary_10_1093_ijnp_pyy082 crossref_primary_10_2147_DHPS_S339170 crossref_primary_10_5498_wjp_v11_i10_696 crossref_primary_10_1002_14651858_CD012807 crossref_primary_10_1097_YIC_0000000000000083 crossref_primary_10_1371_journal_pone_0148212 crossref_primary_10_1093_ijnp_pyy075 crossref_primary_10_1111_1440_1681_12658 crossref_primary_10_1001_jamanetworkopen_2019_21660 crossref_primary_10_1093_schbul_sbu001 crossref_primary_10_1097_JCP_0000000000001933 crossref_primary_10_1007_s40263_018_0539_z crossref_primary_10_1176_appi_ajp_2019_19010034 crossref_primary_10_1016_j_euroneuro_2014_03_001 crossref_primary_10_3389_fpsyt_2018_00231 crossref_primary_10_7717_peerj_8929 crossref_primary_10_7759_cureus_19094 crossref_primary_10_1007_s11126_016_9468_5 crossref_primary_10_1111_jgs_16275 crossref_primary_10_1016_j_psyneuen_2016_06_002 crossref_primary_10_14712_fb2015061030110 crossref_primary_10_1016_j_schres_2018_09_017 crossref_primary_10_1007_s40265_014_0231_7 crossref_primary_10_3389_fphar_2021_830957 crossref_primary_10_1016_j_euroneuro_2014_03_008 crossref_primary_10_1177_0269881118780011 crossref_primary_10_2147_NDT_S313840 crossref_primary_10_3390_biomedicines10123237 crossref_primary_10_1038_s41537_020_00122_3 crossref_primary_10_1016_j_ophtha_2015_09_005 crossref_primary_10_1038_nrdp_2015_67 crossref_primary_10_1186_s13023_020_01379_8 crossref_primary_10_7759_cureus_78251 crossref_primary_10_1016_j_euroneuro_2014_03_012 crossref_primary_10_1021_acs_chemrev_3c00375 crossref_primary_10_1007_s00127_015_1129_8 crossref_primary_10_1007_s12035_023_03555_w crossref_primary_10_1177_2045125317749740 crossref_primary_10_1186_s12888_015_0479_9 crossref_primary_10_1016_j_psychres_2014_06_006 crossref_primary_10_3390_brainsci14010103 crossref_primary_10_1016_j_jpsychires_2013_09_002 crossref_primary_10_1111_acps_12621 crossref_primary_10_1155_2019_3163502 crossref_primary_10_1080_14740338_2024_2362796 crossref_primary_10_4102_sajpsychiatry_v2i0_1772 crossref_primary_10_1017_S1092852922000967 crossref_primary_10_3109_13651501_2014_988268 crossref_primary_10_1016_j_jaac_2018_07_891 crossref_primary_10_3389_fpsyt_2020_00160 crossref_primary_10_1016_j_euroneuro_2020_05_011 crossref_primary_10_1016_S2215_0366_18_30096_8 crossref_primary_10_1111_acps_13131 crossref_primary_10_2147_NDT_S312095 crossref_primary_10_1093_ijnp_pyy045 crossref_primary_10_1038_s41598_021_03761_3 crossref_primary_10_1517_13543784_2014_933806 crossref_primary_10_1097_JCP_0000000000000233 crossref_primary_10_1007_s15202_015_0941_4 crossref_primary_10_16946_kjsr_2021_24_2_52 crossref_primary_10_3389_fspor_2023_1197925 crossref_primary_10_1017_ipm_2025_1 crossref_primary_10_1016_j_bcp_2017_05_009 crossref_primary_10_3389_fpsyt_2021_611070 crossref_primary_10_1002_tcr_202300207 crossref_primary_10_1016_j_hlpt_2019_01_004 crossref_primary_10_1080_14737167_2020_1804873 crossref_primary_10_1016_j_genhosppsych_2023_10_016 crossref_primary_10_1007_s40263_017_0469_1 crossref_primary_10_1177_20451253231168788 crossref_primary_10_2217_fnl_2020_0012 crossref_primary_10_9758_cpn_2021_19_1_117 crossref_primary_10_1177_0272989X211013773 crossref_primary_10_1097_WNF_0000000000000526 crossref_primary_10_1136_eb_2015_102088 crossref_primary_10_36290_psy_2022_006 crossref_primary_10_17116_jnevro2024124111165 crossref_primary_10_30841_2307_5112_1_2_2022_260505 crossref_primary_10_1016_S2215_0366_20_30147_4 crossref_primary_10_1038_s41386_019_0577_3 crossref_primary_10_1136_eb_2015_102086 crossref_primary_10_1186_1741_7015_12_98 crossref_primary_10_1007_s40263_016_0320_0 crossref_primary_10_4103_ATMR_ATMR_182_24 crossref_primary_10_1016_j_mencom_2020_07_027 crossref_primary_10_1007_s40265_019_1052_5 crossref_primary_10_1016_S0140_6736_13_62569_6 crossref_primary_10_1038_s41398_023_02686_x crossref_primary_10_1038_s41398_021_01235_8 crossref_primary_10_1136_eb_2015_102098 crossref_primary_10_1097_YIC_0000000000000024 crossref_primary_10_1016_j_obpill_2023_100066 crossref_primary_10_1111_acps_12276 crossref_primary_10_1111_pcn_12325 crossref_primary_10_1007_s11428_021_00799_9 crossref_primary_10_1097_JCP_0000000000000226 crossref_primary_10_1016_j_neuroscience_2022_03_028 crossref_primary_10_9758_cpn_2021_19_3_568 crossref_primary_10_1080_14740338_2016_1229301 crossref_primary_10_1111_appy_12144 crossref_primary_10_1021_acschemneuro_8b00205 crossref_primary_10_1016_j_jval_2017_03_010 crossref_primary_10_1017_S1092852918001311 crossref_primary_10_1177_0269881117691466 crossref_primary_10_1093_schbul_sbac046 crossref_primary_10_1007_s15005_015_1300_5 crossref_primary_10_1017_S1092852916000444 crossref_primary_10_3389_fpsyt_2022_925757 crossref_primary_10_1007_s00228_019_02739_5 crossref_primary_10_3390_ph14030238 crossref_primary_10_3390_ijms22147671 crossref_primary_10_1093_ijnp_pyy002 crossref_primary_10_1136_bmjopen_2017_019280 crossref_primary_10_1186_s12888_016_0883_9 crossref_primary_10_1186_s12888_023_04851_4 crossref_primary_10_1007_s00702_017_1693_z crossref_primary_10_1016_j_bmc_2015_04_026 crossref_primary_10_1016_j_phrs_2015_03_004 crossref_primary_10_1017_S1092852922000116 crossref_primary_10_1038_s41380_023_02082_3 crossref_primary_10_1039_C6OB00819D crossref_primary_10_3389_fpsyg_2021_768748 crossref_primary_10_5937_racter10_16189 crossref_primary_10_1007_s11606_019_05477_7 crossref_primary_10_1080_13651501_2018_1449864 crossref_primary_10_1016_j_psychres_2024_115895 crossref_primary_10_1016_j_schres_2017_01_002 crossref_primary_10_1111_ejn_15046 crossref_primary_10_1007_s40263_015_0308_1 crossref_primary_10_1097_JCP_0000000000001535 crossref_primary_10_3389_fpsyt_2022_1022472 crossref_primary_10_1017_S0033291721001975 crossref_primary_10_1002_hup_2712 crossref_primary_10_1097_JCP_0000000000000686 crossref_primary_10_4236_ojpsych_2016_61006 crossref_primary_10_1002_hup_2718 crossref_primary_10_17116_jnevro202312307125 crossref_primary_10_1080_03007995_2017_1410471 crossref_primary_10_1021_acschemneuro_7b00001 crossref_primary_10_1177_20451253211034019 crossref_primary_10_1016_j_pnpbp_2017_11_004 crossref_primary_10_1016_j_biopha_2021_111803 crossref_primary_10_1016_j_bpsc_2024_09_001 crossref_primary_10_1111_bcp_14246 crossref_primary_10_1080_15622975_2024_2366235 crossref_primary_10_9758_cpn_2022_20_4_592 crossref_primary_10_1097_JCP_0000000000001507 crossref_primary_10_3389_fpsyt_2024_1425549 crossref_primary_10_1016_j_psyneuen_2015_12_003 crossref_primary_10_1097_JCP_0000000000001502 crossref_primary_10_1097_JCP_0000000000001501 crossref_primary_10_1016_j_jad_2016_07_042 crossref_primary_10_1192_bjp_206_6_521 crossref_primary_10_1002_14651858_CD006324_pub3 crossref_primary_10_1016_j_schres_2016_08_014 crossref_primary_10_1016_j_psycr_2023_100192 crossref_primary_10_1053_j_ajkd_2021_02_328 crossref_primary_10_1007_s40264_014_0145_z crossref_primary_10_1016_j_jpsychires_2023_01_014 crossref_primary_10_1021_acschemneuro_1c00827 crossref_primary_10_1016_j_psyneuen_2016_07_218 crossref_primary_10_1097_JCP_0000000000001513 crossref_primary_10_1097_JCP_0000000000000665 crossref_primary_10_1007_s00508_020_01801_y crossref_primary_10_2217_fnl_14_23 crossref_primary_10_1002_mds_28484 crossref_primary_10_1021_acschemneuro_7b00460 crossref_primary_10_1161_JAHA_114_001568 crossref_primary_10_1177_2045125314540298 crossref_primary_10_1016_j_mpmed_2020_08_004 crossref_primary_10_1007_s40263_016_0363_2 crossref_primary_10_1017_S003329171700349X crossref_primary_10_2478_prilozi_2022_0026 crossref_primary_10_1002_14651858_CD013248 crossref_primary_10_7759_cureus_51240 crossref_primary_10_1016_j_pnpbp_2024_111090 crossref_primary_10_1016_j_bbr_2021_113411 crossref_primary_10_1016_j_neubiorev_2022_104608 crossref_primary_10_1186_s13336_015_0020_x crossref_primary_10_1007_s00115_014_4157_9 crossref_primary_10_1186_1471_244X_14_199 crossref_primary_10_1007_s00127_019_01793_9 crossref_primary_10_1021_acs_jmedchem_4c00195 crossref_primary_10_1517_14656566_2015_1058780 crossref_primary_10_1002_jcla_24949 crossref_primary_10_3109_08039488_2014_983544 crossref_primary_10_1080_00207411_2017_1304075 crossref_primary_10_1016_j_jacl_2017_10_002 crossref_primary_10_1089_cap_2021_0140 crossref_primary_10_1111_nyas_13066 crossref_primary_10_1177_02698811221104055 crossref_primary_10_3389_fpsyt_2023_1183696 crossref_primary_10_1111_eip_12962 crossref_primary_10_1007_s15005_019_0156_5 crossref_primary_10_1002_npr2_12497 crossref_primary_10_3109_09540261_2013_842542 crossref_primary_10_1155_2016_1031794 crossref_primary_10_1155_2020_1638403 crossref_primary_10_1176_appi_ajp_2017_16121358 crossref_primary_10_5234_cnpt_8_16 crossref_primary_10_1097_MJT_0000000000000806 crossref_primary_10_1016_j_bpsc_2019_05_011 crossref_primary_10_3109_13651501_2016_1149195 crossref_primary_10_1017_S0033291720004778 crossref_primary_10_1016_j_eurpsy_2014_09_076 crossref_primary_10_1016_j_eurpsy_2014_09_075 crossref_primary_10_1017_S1041610214001756 crossref_primary_10_1136_bmjopen_2015_010919 crossref_primary_10_1111_nmo_13006 crossref_primary_10_1016_j_heliyon_2024_e24533 crossref_primary_10_1016_j_rpsmen_2021_08_002 crossref_primary_10_1016_j_jad_2023_11_084 crossref_primary_10_1016_j_jad_2020_02_005 crossref_primary_10_1016_j_ajp_2023_103857 crossref_primary_10_1016_j_obpill_2022_100048 crossref_primary_10_1111_bdi_12272 crossref_primary_10_5497_wjp_v8_i2_14 crossref_primary_10_1016_j_psychres_2017_09_051 crossref_primary_10_1038_s41386_020_0764_2 crossref_primary_10_3389_fpsyt_2022_754775 crossref_primary_10_1016_j_schres_2019_08_027 crossref_primary_10_3390_cells8080867 crossref_primary_10_1016_j_schres_2023_03_025 crossref_primary_10_1177_0269881120985166 crossref_primary_10_1016_j_phrs_2017_11_005 crossref_primary_10_1038_s41420_022_01271_3 crossref_primary_10_2147_PGPM_S391401 crossref_primary_10_5012_jkcs_2016_60_2_125 crossref_primary_10_1001_jamapsychiatry_2024_4941 crossref_primary_10_1007_s00406_024_01788_x crossref_primary_10_1016_j_schres_2014_07_025 crossref_primary_10_1176_appi_focus_140308 crossref_primary_10_1002_cpt_2282 crossref_primary_10_3390_ijms20112781 crossref_primary_10_4306_jknpa_2016_55_3_158 crossref_primary_10_1007_s12031_019_01307_x crossref_primary_10_1186_s12888_023_04543_z crossref_primary_10_1007_s00213_017_4646_1 crossref_primary_10_1176_appi_focus_140302 crossref_primary_10_1371_journal_pone_0139155 crossref_primary_10_1007_s40263_016_0350_7 crossref_primary_10_1176_appi_focus_140304 crossref_primary_10_1016_j_euroneuro_2019_09_065 crossref_primary_10_1111_bjc_12041 crossref_primary_10_1007_s11094_019_02059_z crossref_primary_10_1016_j_xcrm_2021_100216 crossref_primary_10_1002_14651858_CD013213 crossref_primary_10_1016_j_psychres_2017_07_038 crossref_primary_10_1016_j_comppsych_2016_01_011 crossref_primary_10_1093_bmb_ldv017 crossref_primary_10_3390_cells11020263 crossref_primary_10_1016_j_jad_2020_11_006 crossref_primary_10_1016_j_obpill_2022_100017 crossref_primary_10_1177_20451253231158152 crossref_primary_10_9740_mhc_2019_03_064 crossref_primary_10_2147_NDT_S413371 crossref_primary_10_17116_jnevro202012006282 crossref_primary_10_1016_S2215_0366_14_70245_7 crossref_primary_10_1371_journal_pone_0107116 crossref_primary_10_2512_jspm_17_97 crossref_primary_10_1177_0004867414536931 crossref_primary_10_1007_s40263_018_0565_x crossref_primary_10_1111_jcpt_12357 crossref_primary_10_1176_appi_ajp_2013_13050650 crossref_primary_10_1186_s12991_017_0170_2 crossref_primary_10_1038_s41398_020_01179_5 crossref_primary_10_1080_17512433_2019_1577134 crossref_primary_10_1016_j_schres_2014_07_015 crossref_primary_10_4155_fmc_13_158 crossref_primary_10_1192_bjp_2024_104 crossref_primary_10_1016_j_psychres_2021_114162 crossref_primary_10_1186_s12888_017_1213_6 crossref_primary_10_1002_hup_2536 crossref_primary_10_1093_schbul_sbx176 crossref_primary_10_1038_s41467_017_00716_z crossref_primary_10_1097_JCP_0000000000000385 crossref_primary_10_1186_s12888_014_0317_5 crossref_primary_10_1080_17425255_2021_1974400 crossref_primary_10_1186_s12916_021_02062_w crossref_primary_10_1016_j_jpsychires_2018_11_005 crossref_primary_10_1016_j_schres_2015_10_005 crossref_primary_10_1111_cob_12105 crossref_primary_10_3389_fpsyt_2020_572102 crossref_primary_10_1016_j_pnpbp_2023_110780 crossref_primary_10_1176_appi_ajp_2015_14121571 crossref_primary_10_1007_s00406_016_0715_4 crossref_primary_10_3389_fpsyt_2019_00835 crossref_primary_10_1021_acschembio_8b00168 crossref_primary_10_1093_ajhp_zxaa303 crossref_primary_10_1192_apt_bp_114_013128 crossref_primary_10_1192_bjo_2017_5 crossref_primary_10_1038_mp_2015_229 crossref_primary_10_3109_01677063_2014_892485 crossref_primary_10_4102_sajpsychiatry_v23i0_1089 crossref_primary_10_2217_cer_2020_0273 crossref_primary_10_1002_wps_20516 crossref_primary_10_1016_j_semerg_2019_06_005 crossref_primary_10_1177_0269881115620460 crossref_primary_10_1016_j_psiq_2016_08_001 crossref_primary_10_1080_17512433_2023_2295428 crossref_primary_10_1186_s12887_016_0710_y crossref_primary_10_1016_j_psychres_2022_114891 crossref_primary_10_1017_S2045796015000694 crossref_primary_10_3390_ijms24032054 crossref_primary_10_3390_ijms22094467 crossref_primary_10_1111_jsr_14360 crossref_primary_10_1016_j_jacl_2014_10_002 crossref_primary_10_1093_ijnp_pyac033 crossref_primary_10_1007_s00228_020_03049_x crossref_primary_10_1517_14740338_2015_974549 crossref_primary_10_1016_j_sleep_2016_04_020 crossref_primary_10_1002_bimj_201900026 crossref_primary_10_1007_s40278_013_4519_2 crossref_primary_10_1038_s41598_021_92204_0 crossref_primary_10_1016_j_schres_2017_07_031 crossref_primary_10_1016_j_jpsychires_2023_11_038 crossref_primary_10_1016_j_jpsychores_2020_109968 crossref_primary_10_1016_j_phymed_2019_153009 crossref_primary_10_1016_j_schres_2017_07_033 crossref_primary_10_1089_cap_2019_0123 crossref_primary_10_1016_j_scitotenv_2018_11_072 crossref_primary_10_1016_j_schres_2017_07_037 crossref_primary_10_1177_2045125318781475 crossref_primary_10_1002_pnp_737 crossref_primary_10_1093_ijnp_pyac047 crossref_primary_10_1007_s40262_016_0465_5 crossref_primary_10_1097_YPG_0000000000000320 crossref_primary_10_1176_appi_ajp_2014_14111465 crossref_primary_10_1016_j_psyneuen_2015_03_012 crossref_primary_10_3390_biomedinformatics3010013 crossref_primary_10_2174_1570159X21666230913152344 crossref_primary_10_1016_j_biopsych_2018_07_003 crossref_primary_10_1038_s41537_020_0107_7 crossref_primary_10_1002_wps_20579 crossref_primary_10_1176_appi_ajp_2019_19040392 crossref_primary_10_1016_j_ejmech_2019_07_050 crossref_primary_10_1080_14740338_2024_2386377 crossref_primary_10_1007_s11920_020_01196_7 crossref_primary_10_1007_s00406_018_0908_0 crossref_primary_10_1016_j_schres_2022_05_021 crossref_primary_10_1016_j_refiri_2021_100241 crossref_primary_10_1371_journal_pone_0298161 crossref_primary_10_1017_S0033291724000370 crossref_primary_10_1002_wps_20567 crossref_primary_10_9758_cpn_23_1075 crossref_primary_10_1097_YCO_0000000000000808 crossref_primary_10_1038_s41467_018_05678_4 crossref_primary_10_1136_gpsych_2018_000016 crossref_primary_10_18632_oncotarget_28010 crossref_primary_10_3389_fpsyt_2023_1126632 crossref_primary_10_1016_j_smrv_2016_05_002 crossref_primary_10_1080_20016689_2017_1372026 crossref_primary_10_1136_gpsych_2019_100091 crossref_primary_10_3389_fphar_2023_1077607 crossref_primary_10_1016_j_clineuro_2018_01_007 crossref_primary_10_1016_j_schres_2015_02_021 crossref_primary_10_1007_s15202_014_0714_0 crossref_primary_10_1186_s12888_018_1856_y crossref_primary_10_1016_j_euroneuro_2017_06_011 crossref_primary_10_1017_S0033291717001271 crossref_primary_10_1017_S1092852915000917 crossref_primary_10_1080_13543784_2016_1256390 crossref_primary_10_1002_14651858_CD003834_pub3 crossref_primary_10_1080_17522439_2022_2134444 crossref_primary_10_3389_fpsyt_2021_710498 crossref_primary_10_3389_fphar_2023_1096366 crossref_primary_10_1093_ijnp_pyac003 crossref_primary_10_1176_appi_ajp_2018_18060639 crossref_primary_10_1002_npr2_12076 crossref_primary_10_2478_jccm_2024_0027 crossref_primary_10_1001_jamapsychiatry_2019_3199 crossref_primary_10_1016_j_ajp_2014_05_006 crossref_primary_10_1056_NEJMoa2017015 crossref_primary_10_1080_24750573_2019_1662629 crossref_primary_10_1016_j_ajp_2014_05_009 crossref_primary_10_1007_s40596_019_01134_7 crossref_primary_10_1016_j_psc_2016_01_006 crossref_primary_10_1111_jcpp_12767 crossref_primary_10_1007_s00406_015_0605_1 crossref_primary_10_1016_j_psc_2016_01_008 crossref_primary_10_1007_s40263_017_0428_x crossref_primary_10_1097_JCP_0000000000001605 crossref_primary_10_1007_s15202_013_0328_y crossref_primary_10_17116_jnevro202212212163 crossref_primary_10_1097_JCP_0000000000000750 crossref_primary_10_1016_j_cca_2022_04_005 crossref_primary_10_1016_j_gtc_2023_08_006 crossref_primary_10_1016_j_schres_2015_04_017 crossref_primary_10_9758_cpn_2019_17_2_314 crossref_primary_10_1016_j_genhosppsych_2015_03_018 crossref_primary_10_1002_14651858_CD012728 crossref_primary_10_54751_revistafoco_v17n5_141 crossref_primary_10_1016_S0140_6736_19_31135_3 crossref_primary_10_1177_0269881114562090 crossref_primary_10_1080_17512433_2021_1865799 crossref_primary_10_9758_cpn_2020_18_3_434 crossref_primary_10_1016_j_conctc_2020_100537 crossref_primary_10_3399_bjgp21X716741 crossref_primary_10_1017_S1092852924002189 crossref_primary_10_1016_j_neuroscience_2017_07_068 crossref_primary_10_1097_YCO_0000000000000417 crossref_primary_10_1017_ipm_2014_18 crossref_primary_10_1186_s40780_021_00227_6 crossref_primary_10_1007_s11428_022_00923_3 crossref_primary_10_1136_bmjopen_2015_010120 crossref_primary_10_1016_j_euroneuro_2015_03_002 crossref_primary_10_1007_s12519_018_0213_z crossref_primary_10_1016_j_jaac_2014_10_002 crossref_primary_10_1155_2022_2677312 crossref_primary_10_1016_j_jad_2021_08_023 crossref_primary_10_1093_schbul_sbu128 crossref_primary_10_3389_fpsyt_2023_1189768 crossref_primary_10_1146_annurev_clinpsy_050718_095514 crossref_primary_10_1177_20451253211046765 crossref_primary_10_1016_j_euroneuro_2018_11_1105 crossref_primary_10_1002_14651858_CD010554_pub2 crossref_primary_10_1007_s00115_015_4275_z crossref_primary_10_1097_JCP_0000000000000734 crossref_primary_10_1016_j_ctim_2018_01_009 crossref_primary_10_1016_j_psiq_2014_07_002 crossref_primary_10_1016_S2215_0366_17_30270_5 crossref_primary_10_1007_s00228_014_1750_6 crossref_primary_10_1007_s00406_015_0618_9 crossref_primary_10_3389_fphar_2020_618184 crossref_primary_10_34883_PI_2020_11_2_009 crossref_primary_10_1177_0706743718777392 crossref_primary_10_1001_jamanetworkopen_2020_4693 crossref_primary_10_1016_j_tem_2019_01_003 crossref_primary_10_1016_S2215_0366_22_00336_4 crossref_primary_10_1097_JCP_0000000000000742 crossref_primary_10_1016_j_psychres_2019_01_045 crossref_primary_10_1038_srep08902 crossref_primary_10_1016_j_jamda_2019_07_009 crossref_primary_10_1192_bjb_2018_61 crossref_primary_10_2478_gp_2018_0007 crossref_primary_10_1016_j_pnpbp_2017_08_010 crossref_primary_10_1038_s41366_023_01291_8 crossref_primary_10_1176_appi_focus_17304 crossref_primary_10_1016_j_ajp_2021_102742 crossref_primary_10_1038_s41380_018_0250_y crossref_primary_10_1016_j_pnpbp_2018_01_023 crossref_primary_10_1016_j_psyneuen_2015_05_014 crossref_primary_10_1136_bmjopen_2014_005708 crossref_primary_10_1016_j_jsxm_2020_03_005 crossref_primary_10_1016_j_schres_2018_02_050 crossref_primary_10_1007_s00213_020_05472_5 crossref_primary_10_1016_j_bbi_2022_03_016 crossref_primary_10_1016_j_neuropharm_2019_05_033 crossref_primary_10_1038_tp_2016_222 crossref_primary_10_1073_pnas_2026403118 crossref_primary_10_1007_s40263_017_0437_9 crossref_primary_10_1016_j_neubiorev_2020_06_028 crossref_primary_10_1080_10826084_2021_1958858 crossref_primary_10_2196_33628 crossref_primary_10_1186_s12916_016_0734_z crossref_primary_10_1016_j_psychres_2018_06_061 crossref_primary_10_52667_2712_9179_2021_1_1_73_83 crossref_primary_10_1055_a_2405_5087 crossref_primary_10_1177_2045125318762365 crossref_primary_10_3760_cma_j_issn_0366_6999_20141193 crossref_primary_10_1016_j_psychres_2016_01_031 crossref_primary_10_1097_YIC_0000000000000177 crossref_primary_10_1155_2018_1543034 crossref_primary_10_2174_1389200223666220201152953 crossref_primary_10_1093_schbul_sbab017 crossref_primary_10_1186_s12888_017_1418_8 crossref_primary_10_1016_j_euroneuro_2017_10_034 crossref_primary_10_1016_j_euroneuro_2018_11_598 crossref_primary_10_1097_YIC_0000000000000189 crossref_primary_10_17795_ijpbs_3561 crossref_primary_10_1038_mp_2015_166 crossref_primary_10_1056_NEJMcpc1900140 crossref_primary_10_1093_schbul_sbab004 crossref_primary_10_1097_YIC_0000000000000182 crossref_primary_10_31857_S0026898423010159 crossref_primary_10_1177_2042098619854886 crossref_primary_10_7554_eLife_84740 crossref_primary_10_1177_0269881118822048 crossref_primary_10_1192_bjp_2019_267 crossref_primary_10_1111_ijcp_14013 crossref_primary_10_1002_emp2_12110 crossref_primary_10_1177_1078390319873049 crossref_primary_10_4306_jknpa_2019_58_1_2 crossref_primary_10_1027_1016_9040_a000400 crossref_primary_10_1080_14737167_2020_1752670 crossref_primary_10_3389_fimmu_2021_660342 crossref_primary_10_1186_s12888_023_05397_1 crossref_primary_10_1186_s13104_017_2679_5 crossref_primary_10_1016_j_schres_2019_10_008 crossref_primary_10_1016_j_bbrc_2015_10_045 crossref_primary_10_1016_j_schres_2024_06_047 crossref_primary_10_1016_j_pharep_2016_04_002 crossref_primary_10_1186_s12888_017_1475_z crossref_primary_10_1093_ijnp_pyx073 crossref_primary_10_1038_s41467_023_41199_5 crossref_primary_10_1016_j_pec_2023_107656 crossref_primary_10_1038_tpj_2016_44 crossref_primary_10_1080_00207411_2024_2368286 crossref_primary_10_1007_s00406_019_01060_7 crossref_primary_10_1080_13651501_2020_1804942 crossref_primary_10_1097_YIC_0000000000000169 crossref_primary_10_1111_pcn_13791 crossref_primary_10_12968_hmed_2018_79_8_444 crossref_primary_10_1093_schbul_sbae135 crossref_primary_10_1097_NMD_0000000000000289 crossref_primary_10_1192_bjpo_bp_116_002766 crossref_primary_10_1007_s11596_020_2214_0 crossref_primary_10_1517_14740338_2014_906579 crossref_primary_10_1093_ageing_afad161 crossref_primary_10_1134_S0026893323010132 crossref_primary_10_1080_14740338_2024_2348561 crossref_primary_10_1016_j_intimp_2024_112904 crossref_primary_10_1186_s12888_015_0650_3 crossref_primary_10_1097_HRP_0000000000000025 crossref_primary_10_1177_00048674211051618 crossref_primary_10_1017_S0033291714001305 crossref_primary_10_3389_fphar_2020_00739 crossref_primary_10_1016_j_neuropharm_2019_05_009 crossref_primary_10_1176_appi_ajp_2017_16091016 crossref_primary_10_1016_j_orcp_2015_08_012 crossref_primary_10_1017_S1092852920002217 crossref_primary_10_1111_acps_12378 crossref_primary_10_1002_14651858_CD008016_pub3 crossref_primary_10_1016_j_neubiorev_2021_01_005 crossref_primary_10_3389_fpsyt_2020_587154 crossref_primary_10_1016_S2215_0366_16_00066_3 crossref_primary_10_1192_bjo_2024_727 crossref_primary_10_3390_biomedicines12112646 crossref_primary_10_1080_14740338_2020_1745184 crossref_primary_10_1016_j_neuropharm_2019_05_015 crossref_primary_10_1177_0004867419885452 crossref_primary_10_1007_s40263_017_0411_6 crossref_primary_10_1097_YIC_0000000000000146 crossref_primary_10_1016_j_psychres_2020_113400 crossref_primary_10_1016_j_schres_2019_10_035 crossref_primary_10_1097_YIC_0000000000000142 crossref_primary_10_3390_cells11010047 crossref_primary_10_1097_YIC_0000000000000140 crossref_primary_10_1177_0706743717719898 crossref_primary_10_1111_biom_13573 crossref_primary_10_1186_s12888_016_1121_1 crossref_primary_10_1007_s00115_013_3913_6 crossref_primary_10_1093_schizbullopen_sgaa014 crossref_primary_10_1002_wps_20187 crossref_primary_10_1097_JCP_0000000000001679 crossref_primary_10_1176_appi_ajp_2020_19121279 crossref_primary_10_1016_j_vhri_2019_08_474 crossref_primary_10_1016_j_schres_2021_08_005 crossref_primary_10_1080_17522439_2021_1930119 crossref_primary_10_3389_fpsyt_2022_983999 crossref_primary_10_1007_s00406_023_01580_3 crossref_primary_10_1038_s41467_019_10800_1 crossref_primary_10_1111_acps_13212 crossref_primary_10_1136_bmjopen_2015_007848 crossref_primary_10_5455_bcp_20150630080048 crossref_primary_10_1016_j_schres_2020_11_025 crossref_primary_10_1097_JCP_0000000000000798 crossref_primary_10_1007_s40264_025_01526_9 crossref_primary_10_1097_PRA_0000000000000117 crossref_primary_10_1007_s00210_018_1500_x crossref_primary_10_1016_j_heliyon_2023_e18319 crossref_primary_10_1016_j_ajp_2019_08_010 crossref_primary_10_1016_j_psychres_2016_03_025 crossref_primary_10_3238_arztebl_2020_0412 crossref_primary_10_1007_s40263_013_0105_7 crossref_primary_10_1177_0269881118754708 crossref_primary_10_1016_j_psyneuen_2018_03_021 crossref_primary_10_1136_bmjopen_2021_057286 crossref_primary_10_1021_acschemneuro_6b00371 crossref_primary_10_4236_ojpsych_2018_82012 crossref_primary_10_1038_s41598_022_16130_5 crossref_primary_10_1097_YIC_0000000000000123 crossref_primary_10_2217_pgs_14_158 crossref_primary_10_3371_CSRP_CIWE_103114 crossref_primary_10_1111_acps_12374 crossref_primary_10_3389_fpsyt_2022_970210 crossref_primary_10_1016_j_neuropharm_2019_107704 crossref_primary_10_1002_pdi_1891 crossref_primary_10_1016_j_rpsmen_2016_09_001 crossref_primary_10_1016_j_schres_2020_11_014 crossref_primary_10_1136_bmjdrc_2019_001036 crossref_primary_10_1016_j_rpsm_2018_02_005 crossref_primary_10_1016_j_schres_2020_11_010 crossref_primary_10_1007_s40263_014_0196_9 crossref_primary_10_1017_S0033291715001701 crossref_primary_10_1007_s40263_016_0367_y crossref_primary_10_1515_jbcpp_2016_0115 crossref_primary_10_1016_j_euroneuro_2018_03_008 crossref_primary_10_1016_j_euroneuro_2018_03_004 crossref_primary_10_1007_s13311_020_00898_3 crossref_primary_10_3389_fpsyt_2021_681418 crossref_primary_10_1080_01612840_2025_2476156 crossref_primary_10_1016_j_pbb_2015_09_006 crossref_primary_10_1016_j_psychres_2023_115217 crossref_primary_10_1016_j_bbi_2015_10_019 crossref_primary_10_1080_09638237_2019_1677866 crossref_primary_10_1177_0004867416641195 crossref_primary_10_1007_s11892_015_0704_4 crossref_primary_10_1186_s12906_018_2090_3 crossref_primary_10_3390_medicina58020213 crossref_primary_10_1007_s15005_018_2458_4 crossref_primary_10_1177_0269881116645254 crossref_primary_10_1093_schbul_sby095 crossref_primary_10_1007_s00415_017_8621_x crossref_primary_10_1021_acsomega_2c06569 crossref_primary_10_3389_fphar_2020_572396 crossref_primary_10_1002_14651858_CD015332 crossref_primary_10_1097_JCP_0000000000000305 crossref_primary_10_9740_mhc_2015_03_063 crossref_primary_10_1177_00048674241256839 crossref_primary_10_1016_j_revmed_2016_12_007 crossref_primary_10_1177_00912174231214647 crossref_primary_10_5937_arhfarm71_31163 crossref_primary_10_1007_s00115_024_01608_6 crossref_primary_10_3390_molecules27010196 crossref_primary_10_1016_j_psychres_2016_06_031 crossref_primary_10_1097_YIC_0000000000000311 crossref_primary_10_1038_s41398_017_0008_3 crossref_primary_10_1016_j_pnpbp_2023_110831 crossref_primary_10_1186_s12991_024_00542_w crossref_primary_10_1124_jpet_113_212373 crossref_primary_10_1002_psp4_12692 crossref_primary_10_1016_j_psychres_2018_09_014 crossref_primary_10_1007_s00115_024_01790_7 crossref_primary_10_1016_j_psiq_2018_11_002 crossref_primary_10_3389_fpsyt_2019_00314 crossref_primary_10_1007_s00702_015_1400_x crossref_primary_10_17116_jnevro20161167155_58 crossref_primary_10_1080_14789949_2017_1332773 crossref_primary_10_2139_ssrn_3988000 crossref_primary_10_1080_23794925_2018_1514546 crossref_primary_10_5498_wjp_v6_i4_442 crossref_primary_10_1177_00048674231209840 crossref_primary_10_1517_14740338_2016_1161021 crossref_primary_10_1016_j_pharep_2017_12_003 crossref_primary_10_1007_s40264_022_01252_6 crossref_primary_10_1017_ipm_2020_12 crossref_primary_10_1111_pcn_12508 crossref_primary_10_3389_fphar_2022_863588 crossref_primary_10_3389_fpsyt_2020_00456 crossref_primary_10_1002_14651858_CD012145_pub2 crossref_primary_10_1016_j_pnpbp_2021_110250 crossref_primary_10_1007_s11126_020_09762_1 crossref_primary_10_1080_17522439_2023_2183428 crossref_primary_10_1016_j_schres_2016_03_021 crossref_primary_10_1007_s40501_017_0113_1 crossref_primary_10_1177_0269881120907972 crossref_primary_10_1097_FTD_0000000000001184 crossref_primary_10_1016_S2215_0366_23_00262_6 crossref_primary_10_3390_toxics9120339 crossref_primary_10_1038_s41598_018_31122_0 crossref_primary_10_1177_0091217416636578 crossref_primary_10_1016_j_rpsm_2016_09_003 crossref_primary_10_16946_kjsr_2019_22_2_21 crossref_primary_10_1073_pnas_1504196112 crossref_primary_10_1097_YIC_0000000000000300 crossref_primary_10_3390_ijms242115623 crossref_primary_10_1021_acschemneuro_6b00432 crossref_primary_10_1177_0269881121991567 crossref_primary_10_1016_j_pharmthera_2018_06_012 crossref_primary_10_1007_s00213_017_4747_x crossref_primary_10_1007_s40273_015_0285_8 crossref_primary_10_2174_1570159X22666240815120547 crossref_primary_10_5334_tohm_695 crossref_primary_10_1177_0269881118773026 crossref_primary_10_1517_14740338_2016_1141893 crossref_primary_10_1038_s41386_019_0464_y crossref_primary_10_30629_0023_2149_2023_101_9_10_467_473 crossref_primary_10_3111_13696998_2014_897627 crossref_primary_10_1080_14740338_2020_1795126 crossref_primary_10_1016_j_nbd_2018_08_016 crossref_primary_10_1007_s00213_022_06119_3 crossref_primary_10_3389_fpsyt_2022_925583 crossref_primary_10_1586_17512433_2016_1121809 crossref_primary_10_3399_bjgp18X695381 crossref_primary_10_1016_S0140_6736_15_01121_6 crossref_primary_10_1007_s11126_021_09937_4 crossref_primary_10_3109_09638237_2015_1036974 crossref_primary_10_1093_schbul_sby153 crossref_primary_10_1016_j_eurpsy_2018_07_004 crossref_primary_10_3389_fncir_2021_769969 crossref_primary_10_1093_ajhp_zxaa224 crossref_primary_10_1093_ijnp_pyv121 crossref_primary_10_5712_rbmfc18_45_2930 crossref_primary_10_1016_j_schres_2019_10_057 crossref_primary_10_1001_jamapsychiatry_2024_2890 crossref_primary_10_1016_S2215_0366_16_30171_7 crossref_primary_10_3390_molecules23082087 crossref_primary_10_1016_j_pnpbp_2017_03_020 crossref_primary_10_1177_0706743719828968 crossref_primary_10_1186_s13052_016_0259_2 crossref_primary_10_1007_s00406_015_0624_y crossref_primary_10_1017_S2045796017000245 crossref_primary_10_1007_s11481_015_9605_1 crossref_primary_10_1016_j_forsciint_2020_110435 crossref_primary_10_1177_0363546515580787 crossref_primary_10_1186_s12888_022_04179_5 crossref_primary_10_1212_CPJ_0000000000000344 crossref_primary_10_1111_jpm_12249 crossref_primary_10_1016_j_schres_2024_05_017 crossref_primary_10_1080_17512433_2022_2118111 crossref_primary_10_1016_j_schres_2016_12_029 crossref_primary_10_1186_1471_244X_13_241 crossref_primary_10_1007_s00213_014_3459_8 crossref_primary_10_1016_j_psym_2017_10_009 crossref_primary_10_1016_j_ccc_2017_03_008 crossref_primary_10_1016_j_jclinepi_2022_12_025 crossref_primary_10_1016_j_schres_2024_12_015 crossref_primary_10_3389_fpsyt_2024_1382013 crossref_primary_10_1007_s00406_024_01763_6 crossref_primary_10_1097_JCP_0000000000000494 crossref_primary_10_1053_j_ajkd_2016_07_033 crossref_primary_10_1098_rsob_180031 crossref_primary_10_1080_24750573_2018_1533190 crossref_primary_10_1016_j_schres_2016_12_017 crossref_primary_10_1007_s00210_019_01665_8 crossref_primary_10_1016_S2215_0366_16_30354_6 crossref_primary_10_3390_pharmaceutics14050978 crossref_primary_10_1016_j_phrs_2015_06_003 crossref_primary_10_1111_eip_12428 crossref_primary_10_36290_psy_2021_021 crossref_primary_10_1177_0269881113515064 crossref_primary_10_1177_070674371405900801 crossref_primary_10_3390_biomedicines11020314 crossref_primary_10_1016_S2215_0366_24_00366_3 crossref_primary_10_1016_j_ajp_2024_104047 crossref_primary_10_1016_j_psychres_2021_114227 crossref_primary_10_3233_JAD_200994 crossref_primary_10_1097_JCP_0000000000000904 crossref_primary_10_1016_j_psychres_2022_114500 crossref_primary_10_1111_acps_12952 crossref_primary_10_4306_jknpa_2019_58_1_29 crossref_primary_10_4236_ojpsych_2023_133016 crossref_primary_10_1017_S0033291716002476 crossref_primary_10_1192_bja_2017_21 crossref_primary_10_5937_PsihDan2001113M crossref_primary_10_1007_s00213_014_3780_2 crossref_primary_10_1016_j_brainres_2022_147889 crossref_primary_10_1136_bmjopen_2020_043259 crossref_primary_10_1016_j_ajp_2014_03_007 crossref_primary_10_1136_dtb_2015_3_0313 crossref_primary_10_2174_1570163820666230606113158 crossref_primary_10_1007_s00228_019_02768_0 crossref_primary_10_1136_bmjopen_2015_008572 crossref_primary_10_9758_cpn_2022_20_2_373 crossref_primary_10_1192_j_eurpsy_2020_72 crossref_primary_10_1016_S2215_0366_21_00500_9 crossref_primary_10_1016_j_schres_2018_08_028 crossref_primary_10_1136_bmjopen_2021_059096 crossref_primary_10_1080_14740338_2016_1199681 crossref_primary_10_1186_s12906_017_1901_2 crossref_primary_10_1016_j_cellsig_2020_109732 crossref_primary_10_1016_j_euroneuro_2016_03_008 crossref_primary_10_1007_s40273_016_0405_0 crossref_primary_10_1016_j_lpmope_2023_100043 crossref_primary_10_1080_08039488_2020_1755995 crossref_primary_10_1017_S1478951518000962 crossref_primary_10_1176_appi_ajp_2020_20091425 crossref_primary_10_3390_ijms21072345 crossref_primary_10_1002_14651858_CD014834 crossref_primary_10_1016_j_mpmed_2016_09_018 crossref_primary_10_1080_24750573_2017_1370767 crossref_primary_10_1016_j_ajp_2017_01_005 crossref_primary_10_1016_j_bbr_2021_113710 crossref_primary_10_1016_j_mcna_2022_05_005 crossref_primary_10_1016_j_brainres_2016_08_010 crossref_primary_10_1016_j_ejpsy_2024_100259 crossref_primary_10_1093_aje_kwx355 crossref_primary_10_1016_j_biopsych_2017_12_006 crossref_primary_10_1002_mgg3_869 crossref_primary_10_1080_00332747_2018_1550735 crossref_primary_10_1016_j_banm_2020_10_005 crossref_primary_10_7759_cureus_65939 crossref_primary_10_1097_JCP_0000000000000900 crossref_primary_10_1016_S0140_6736_13_62617_3 crossref_primary_10_1177_2045125315596697 crossref_primary_10_1053_j_gastro_2016_12_049 crossref_primary_10_1007_s13311_017_0552_9 crossref_primary_10_1002_14651858_CD015332_pub2 crossref_primary_10_4306_jknpa_2019_58_1_12 crossref_primary_10_1007_s00213_014_3540_3 crossref_primary_10_1007_s40199_019_00281_4 crossref_primary_10_1016_j_powtec_2018_08_072 crossref_primary_10_1136_bcr_2015_212149 crossref_primary_10_1111_bcpt_13323 crossref_primary_10_3390_ijms21249532 crossref_primary_10_1089_cap_2020_0052 crossref_primary_10_1007_s00213_021_06042_z crossref_primary_10_1080_14737175_2017_1283217 crossref_primary_10_1016_j_jaac_2015_06_015 crossref_primary_10_1016_j_sjbs_2020_11_044 crossref_primary_10_5694_mja2_50383 crossref_primary_10_1007_s40211_023_00473_0 crossref_primary_10_1192_bjo_2020_51 crossref_primary_10_1002_pds_4187 crossref_primary_10_1080_03007995_2018_1498779 crossref_primary_10_1017_S2045796015000980 crossref_primary_10_1016_j_bbi_2020_07_043 crossref_primary_10_3389_fpubh_2022_987408 crossref_primary_10_3390_biomedicines12030494 crossref_primary_10_7326_M14_2385 crossref_primary_10_1093_schbul_sbv019 crossref_primary_10_3389_fendo_2020_573479 crossref_primary_10_3390_ijerph18189922 crossref_primary_10_1186_s13643_017_0572_x crossref_primary_10_1177_0306624X241282279 crossref_primary_10_1017_neu_2016_57 crossref_primary_10_1155_2014_791573 crossref_primary_10_1093_schbul_sbv037 crossref_primary_10_1002_npr2_12193 crossref_primary_10_1016_j_jaci_2020_08_027 crossref_primary_10_1002_pbc_27289 crossref_primary_10_1002_wps_20425 crossref_primary_10_1038_mp_2016_121 crossref_primary_10_1007_s40261_020_00913_7 crossref_primary_10_12968_bjmh_2015_4_4_157 crossref_primary_10_1177_1039856216641309 crossref_primary_10_3389_fendo_2020_00195 crossref_primary_10_9758_cpn_2022_20_3_567 crossref_primary_10_1007_s00787_021_01899_z crossref_primary_10_1007_s00787_020_01582_9 crossref_primary_10_4103_TPSY_TPSY_26_21 crossref_primary_10_1093_schbul_sbv125 crossref_primary_10_1038_nrd3893 crossref_primary_10_1016_j_schres_2014_02_002 crossref_primary_10_1007_s00739_019_0584_5 crossref_primary_10_1016_S2215_0366_19_30132_4 crossref_primary_10_1136_eb_2016_102532 crossref_primary_10_1586_14737167_2014_891443 crossref_primary_10_1001_jamanetworkopen_2020_5888 crossref_primary_10_1038_s41537_023_00378_5 crossref_primary_10_1017_S1352465816000060 crossref_primary_10_1089_cap_2020_0093 crossref_primary_10_1097_PRA_0000000000000288 crossref_primary_10_1080_13696998_2018_1521415 crossref_primary_10_1176_appi_focus_18306 crossref_primary_10_1007_s00406_015_0596_y crossref_primary_10_1016_S2215_0366_23_00005_6 crossref_primary_10_1186_s12888_017_1406_z crossref_primary_10_1016_j_schres_2018_11_031 crossref_primary_10_1016_j_csbj_2024_01_003 crossref_primary_10_1016_j_euroneuro_2019_03_007 crossref_primary_10_1016_j_genhosppsych_2015_11_008 crossref_primary_10_1097_PSY_0000000000000863 crossref_primary_10_1016_j_nsa_2025_105507 crossref_primary_10_1016_j_jpsychires_2024_11_047 crossref_primary_10_1007_s00115_013_3807_7 crossref_primary_10_1186_s12888_016_0756_2 crossref_primary_10_3390_ijms160923012 crossref_primary_10_1186_s12888_021_03473_y crossref_primary_10_3390_ijms19103105 crossref_primary_10_1017_S1368980024001988 crossref_primary_10_1007_s11013_016_9517_4 crossref_primary_10_3390_medicina58111584 crossref_primary_10_1097_JCP_0000000000000850 crossref_primary_10_1177_0269881117711709 crossref_primary_10_1186_s12888_015_0557_z crossref_primary_10_1002_14651858_CD014384_pub2 crossref_primary_10_1001_jamapsychiatry_2019_4379 crossref_primary_10_1002_jcph_1365 crossref_primary_10_1016_j_jpsychires_2022_07_015 crossref_primary_10_1192_bjo_2022_619 crossref_primary_10_1371_journal_pone_0081208 crossref_primary_10_1016_S2215_0366_15_00553_2 crossref_primary_10_1002_14651858_CD012429_pub2 crossref_primary_10_1017_neu_2022_9 crossref_primary_10_1007_s11920_017_0847_x crossref_primary_10_1371_journal_pone_0119931 crossref_primary_10_5498_wjp_v13_i11_937 crossref_primary_10_1038_s41397_018_0033_5 crossref_primary_10_3389_fpsyt_2018_00018 crossref_primary_10_1016_S2215_0366_19_30398_0 crossref_primary_10_1586_14737175_2015_1086269 crossref_primary_10_1176_appi_ajp_2020_20111657 crossref_primary_10_1055_a_2290_6386 crossref_primary_10_1093_schbul_sbac203 crossref_primary_10_1016_j_jpsychires_2020_02_026 crossref_primary_10_18261_issn_1504_3010_2017_01_02 crossref_primary_10_1097_JCP_0000000000000834 crossref_primary_10_1007_s41669_017_0058_8 crossref_primary_10_1016_j_eurpsy_2015_07_004 crossref_primary_10_3389_fpsyt_2023_1183912 crossref_primary_10_1089_cap_2015_0024 crossref_primary_10_1136_bmjopen_2023_077173 crossref_primary_10_1016_j_schres_2015_11_002 crossref_primary_10_1038_s41398_021_01482_9 crossref_primary_10_1080_15622975_2020_1795254 crossref_primary_10_1186_s12874_018_0534_6 crossref_primary_10_1016_j_encep_2014_07_004 crossref_primary_10_1056_NEJMoa1911772 crossref_primary_10_3390_jpm13050801 crossref_primary_10_1016_S2215_0366_15_00575_1 crossref_primary_10_1080_14999013_2023_2218287 crossref_primary_10_1016_j_neulet_2021_136098 crossref_primary_10_1007_s40120_020_00212_5 crossref_primary_10_1176_appi_ps_20240110 crossref_primary_10_1038_s41467_018_04489_x crossref_primary_10_1177_0269881119872193 crossref_primary_10_1017_S2045796015000906 crossref_primary_10_1016_j_euroneuro_2019_12_117 crossref_primary_10_1016_j_euroneuro_2019_12_118 crossref_primary_10_1016_j_schres_2020_08_006 crossref_primary_10_1177_0269881115581093 crossref_primary_10_3390_pharmacy11060175 crossref_primary_10_1016_j_jpsychires_2019_06_002 crossref_primary_10_1016_j_psycr_2022_100063 crossref_primary_10_1016_j_fct_2024_114490 crossref_primary_10_1016_j_euroneuro_2015_11_006 crossref_primary_10_1097_YIC_0000000000000292 crossref_primary_10_1176_appi_ajp_2015_14091200 crossref_primary_10_1186_s12888_017_1539_0 crossref_primary_10_1080_13554794_2022_2114838 crossref_primary_10_1007_s40265_017_0789_y crossref_primary_10_1007_s00213_016_4450_3 crossref_primary_10_1016_j_comppsych_2014_07_018 crossref_primary_10_1007_s10787_023_01293_y crossref_primary_10_1007_s40801_016_0084_3 crossref_primary_10_3389_fpsyt_2018_00488 crossref_primary_10_1016_j_euroneuro_2021_10_449 crossref_primary_10_3389_fpsyt_2022_892199 crossref_primary_10_1097_JCP_0000000000000817 crossref_primary_10_1007_s40273_015_0348_x crossref_primary_10_1002_JPER_19_0593 crossref_primary_10_1176_appi_ps_202000066 crossref_primary_10_1371_journal_pone_0123153 crossref_primary_10_1038_s41537_024_00505_w crossref_primary_10_1186_s40779_022_00420_0 crossref_primary_10_1080_17512433_2016_1191945 crossref_primary_10_1002_14651858_CD013100_pub2 crossref_primary_10_1038_mp_2014_56 crossref_primary_10_1177_10600280241290254 crossref_primary_10_1016_j_psychres_2019_112671 crossref_primary_10_1097_HRP_0000000000000120 crossref_primary_10_1176_appi_ajp_2015_14101275 crossref_primary_10_1371_journal_pone_0218711 crossref_primary_10_15406_jpcpy_2020_11_00673 crossref_primary_10_1111_dom_14270 crossref_primary_10_1016_j_schres_2020_06_026 crossref_primary_10_1136_bmjopen_2016_013881 crossref_primary_10_1186_s12916_014_0126_1 crossref_primary_10_1017_S1092852918001104 crossref_primary_10_1038_tpj_2015_90 crossref_primary_10_1007_s40266_018_0579_6 crossref_primary_10_1016_j_euroneuro_2016_07_010 crossref_primary_10_1177_0269881118795333 crossref_primary_10_1017_S1092852920001698 crossref_primary_10_1001_jamapsychiatry_2017_2943 crossref_primary_10_1210_clinem_dgab421 crossref_primary_10_1016_j_schres_2024_10_018 crossref_primary_10_1038_s41398_020_00888_1 crossref_primary_10_30773_pi_2020_0306 crossref_primary_10_1016_j_bionps_2020_100025 crossref_primary_10_1007_s00406_014_0511_y crossref_primary_10_1186_s12888_021_03037_0 crossref_primary_10_1176_appi_prcp_20200004 crossref_primary_10_1007_s40120_016_0050_8 crossref_primary_10_1097_JCP_0000000000001303 crossref_primary_10_1097_YCO_0000000000000160 crossref_primary_10_1177_02698811211026456 crossref_primary_10_1186_s40345_019_0145_0 crossref_primary_10_1212_WNL_0000000000007466 crossref_primary_10_1177_20451253221117313 crossref_primary_10_1016_j_bionps_2020_100017 crossref_primary_10_1016_j_jaac_2019_01_015 crossref_primary_10_3310_hta21490 crossref_primary_10_1186_s12991_017_0166_y crossref_primary_10_1001_jamapsychiatry_2019_1702 crossref_primary_10_1016_j_rpsmen_2018_02_012 crossref_primary_10_1017_S1092852917000402 crossref_primary_10_2147_DDDT_S327506 crossref_primary_10_1016_j_rcp_2015_05_003 crossref_primary_10_3389_fpsyt_2023_1153648 crossref_primary_10_1093_schbul_sbae034 crossref_primary_10_1186_1471_244X_14_102 crossref_primary_10_1016_j_euroneuro_2017_02_005 crossref_primary_10_1016_j_rpsmen_2014_10_004 crossref_primary_10_1371_journal_pone_0094112 crossref_primary_10_1080_20016689_2018_1508272 crossref_primary_10_1093_ijnp_pyw076 crossref_primary_10_1016_S2215_0366_14_70314_1 crossref_primary_10_1038_s41467_024_44874_3 crossref_primary_10_1586_17512433_2014_865515 crossref_primary_10_1007_s40263_014_0177_z crossref_primary_10_1007_s15202_014_0909_4 crossref_primary_10_1185_03007995_2014_908280 crossref_primary_10_1186_s12888_017_1289_z crossref_primary_10_1371_journal_pone_0308037 crossref_primary_10_9758_cpn_2022_20_3_526 crossref_primary_10_1038_s42255_025_01252_7 crossref_primary_10_1192_bjp_bp_114_155945 crossref_primary_10_1016_j_jclinepi_2015_05_027 crossref_primary_10_1016_j_psychres_2017_05_038 crossref_primary_10_1177_0269881115602490 crossref_primary_10_1891_1559_4343_17_3_176 crossref_primary_10_1177_2045125318754472 crossref_primary_10_4103_jmedsci_jmedsci_410_20 crossref_primary_10_1093_schbul_sbz087 crossref_primary_10_9758_cpn_2019_17_2_250 crossref_primary_10_1177_20420986241233842 crossref_primary_10_1002_14651858_CD014383 crossref_primary_10_1016_j_neulet_2019_134292 crossref_primary_10_1002_14651858_CD014384 crossref_primary_10_1016_j_schres_2019_05_020 crossref_primary_10_1016_j_encep_2014_09_002 crossref_primary_10_1080_01612840_2022_2158683 crossref_primary_10_1152_jn_00387_2015 crossref_primary_10_1176_appi_focus_130105 crossref_primary_10_1186_s13321_017_0198_y crossref_primary_10_1371_journal_pmed_1003455 crossref_primary_10_1001_jamapsychiatry_2020_3643 crossref_primary_10_1007_s40262_019_00744_6 crossref_primary_10_1186_s13584_016_0074_7 crossref_primary_10_1111_jcpp_12461 crossref_primary_10_1136_gpsych_2018_100016 crossref_primary_10_1007_s40501_017_0131_z crossref_primary_10_1080_00032719_2020_1728291 crossref_primary_10_3389_fpsyt_2022_1037738 crossref_primary_10_1080_14737175_2021_1942845 crossref_primary_10_1186_s13018_025_05520_w crossref_primary_10_1007_s10597_024_01347_7 crossref_primary_10_1016_S0140_6736_13_61032_6 crossref_primary_10_1016_j_rpsm_2020_05_003 crossref_primary_10_1080_10503307_2017_1321805 crossref_primary_10_1093_schbul_sbz068 crossref_primary_10_1186_s41983_021_00359_4 crossref_primary_10_1293_tox_2019_0004 crossref_primary_10_1093_schbul_sbz064 crossref_primary_10_1002_pmic_201500242 crossref_primary_10_1016_j_rpsmen_2021_07_001 crossref_primary_10_1038_s44220_023_00109_w crossref_primary_10_1254_fpj_154_275 crossref_primary_10_1097_01_EHX_0000481739_67440_8f crossref_primary_10_1017_S1041610219000255 crossref_primary_10_1001_jamapsychiatry_2018_4489 crossref_primary_10_1111_bcp_13145 crossref_primary_10_1016_j_jemermed_2017_11_031 crossref_primary_10_1111_acps_12468 crossref_primary_10_1007_s00702_024_02818_7 crossref_primary_10_1007_s11126_018_9606_3 crossref_primary_10_1038_s41401_019_0285_x crossref_primary_10_1136_dtb_2024_259154rep crossref_primary_10_1177_0020764020924698 crossref_primary_10_1177_1039856216632399 crossref_primary_10_1002_jcph_1911 crossref_primary_10_1038_s12276_021_00580_4 crossref_primary_10_1097_WNF_0000000000000226 crossref_primary_10_1186_s13643_015_0005_7 crossref_primary_10_1016_j_schres_2015_01_035 crossref_primary_10_1038_npp_2015_196 crossref_primary_10_1002_ddr_21800 crossref_primary_10_1016_j_schres_2015_01_038 crossref_primary_10_1111_papt_12367 crossref_primary_10_1016_j_jbtep_2015_02_007 crossref_primary_10_1002_14651858_CD015665 crossref_primary_10_1074_jbc_RA118_004682 crossref_primary_10_1517_14656566_2016_1149164 crossref_primary_10_1080_14656566_2018_1543409 crossref_primary_10_1176_appi_ps_201700162 crossref_primary_10_2174_0929867327666200907141452 crossref_primary_10_1016_j_schres_2023_02_024 crossref_primary_10_1097_JCP_0000000000000196 crossref_primary_10_1080_14740338_2020_1832990 crossref_primary_10_1097_YIC_0000000000000448 crossref_primary_10_1097_JCP_0000000000001052 crossref_primary_10_1016_j_neubiorev_2017_09_027 crossref_primary_10_1111_eip_12716 crossref_primary_10_1002_14651858_CD013493 crossref_primary_10_1080_07053436_2017_1328783 crossref_primary_10_1136_eb_2014_101795 crossref_primary_10_1097_MD_0000000000026912 crossref_primary_10_1111_jcpt_13432 crossref_primary_10_1016_j_jad_2020_03_030 crossref_primary_10_3389_fpsyt_2024_1382326 crossref_primary_10_1517_13543784_2015_1009976 crossref_primary_10_1002_14651858_CD011883_pub2 crossref_primary_10_2174_1568026619666190712210903 crossref_primary_10_1111_bcpt_12720 crossref_primary_10_1016_j_schres_2020_12_008 crossref_primary_10_1016_j_compbiomed_2019_05_007 crossref_primary_10_1016_j_schres_2020_12_006 crossref_primary_10_1016_j_jadohealth_2023_04_022 crossref_primary_10_1177_1060028019829494 crossref_primary_10_1177_1745691616649170 crossref_primary_10_1186_s12991_020_00292_5 crossref_primary_10_5498_wjp_v12_i3_521 crossref_primary_10_1136_bcr_2023_259154 crossref_primary_10_1002_wps_21205 crossref_primary_10_1016_j_schres_2022_08_015 crossref_primary_10_1192_bja_2018_50 crossref_primary_10_1007_s40258_015_0176_3 crossref_primary_10_1016_j_bbr_2016_02_019 crossref_primary_10_1016_j_clinthera_2019_11_009 crossref_primary_10_2512_jspm_16_133 crossref_primary_10_1016_j_schres_2017_04_002 crossref_primary_10_1080_08039488_2017_1400097 crossref_primary_10_1007_s40501_015_0043_8 crossref_primary_10_3390_jcm11154530 crossref_primary_10_1016_j_pneurobio_2014_08_002 crossref_primary_10_1016_j_schres_2019_07_020 crossref_primary_10_1097_JCP_0000000000001480 crossref_primary_10_1080_14740338_2021_1939304 crossref_primary_10_1007_s00210_024_03209_1 crossref_primary_10_1176_appi_ajp_20240738 crossref_primary_10_1016_j_clineuro_2020_105853 crossref_primary_10_3389_fphar_2023_1264591 crossref_primary_10_1097_JCP_0000000000000157 crossref_primary_10_1097_JCP_0000000000001488 crossref_primary_10_1016_j_gene_2017_07_005 crossref_primary_10_1097_YIC_0000000000000404 crossref_primary_10_2174_2666082218666211221090624 crossref_primary_10_1016_j_pnpbp_2018_04_006 crossref_primary_10_1055_s_0042_118429 crossref_primary_10_1111_acps_13066 crossref_primary_10_1016_j_psychres_2015_03_019 crossref_primary_10_1002_sim_6364 crossref_primary_10_1016_j_euroneuro_2019_06_008 crossref_primary_10_1001_jama_2019_10517 crossref_primary_10_1007_s00213_018_5133_z crossref_primary_10_1176_appi_focus_12_2_184 crossref_primary_10_1007_s11845_023_03284_y crossref_primary_10_1038_s41380_018_0269_0 crossref_primary_10_1097_JCP_0000000000001013 crossref_primary_10_1007_s00213_016_4445_0 crossref_primary_10_1177_0004867417720516 crossref_primary_10_1016_j_euroneuro_2017_03_003 crossref_primary_10_1176_appi_ajp_2013_13081129 crossref_primary_10_1002_phar_2404 crossref_primary_10_1016_j_bmc_2014_09_024 crossref_primary_10_1016_j_schres_2020_03_006 crossref_primary_10_2174_1389450120666181105152439 crossref_primary_10_1002_bkcs_10891 crossref_primary_10_1038_s41398_023_02501_7 crossref_primary_10_1007_s15202_017_1495_z crossref_primary_10_1111_eip_12774 crossref_primary_10_1002_sim_7223 crossref_primary_10_1080_17512433_2017_1345623 crossref_primary_10_1080_03007995_2018_1532883 crossref_primary_10_1016_j_bpsc_2019_04_002 crossref_primary_10_2147_IPRP_S271814 crossref_primary_10_1017_ipm_2020_1 crossref_primary_10_1038_s41380_020_0791_8 crossref_primary_10_1007_s00406_019_01063_4 crossref_primary_10_3389_fpsyt_2020_00152 crossref_primary_10_2174_1574884713666181102145236 crossref_primary_10_1016_j_jprot_2020_103813 crossref_primary_10_1016_j_rpsmen_2016_06_001 crossref_primary_10_1159_000445802 crossref_primary_10_1080_14656566_2022_2145884 crossref_primary_10_1192_bja_2018_25 crossref_primary_10_1007_s00787_019_01313_9 crossref_primary_10_1016_j_ajp_2015_05_005 crossref_primary_10_1016_j_euroneuro_2013_09_001 crossref_primary_10_16946_kjsr_2017_20_2_69 crossref_primary_10_1016_j_eurpsy_2017_04_001 crossref_primary_10_1177_2045125321991278 crossref_primary_10_1517_14740338_2014_908183 crossref_primary_10_1111_jep_12448 crossref_primary_10_3389_fnins_2017_00643 crossref_primary_10_1007_s15202_019_2202_z crossref_primary_10_1176_appi_ajp_2015_15060741 crossref_primary_10_1017_S003329171900285X crossref_primary_10_1002_14651858_CD012052_pub2 crossref_primary_10_1016_j_ajp_2018_03_012 crossref_primary_10_1097_MD_0000000000013688 crossref_primary_10_3109_15622975_2015_1083616 crossref_primary_10_1097_FTD_0000000000000582 crossref_primary_10_1192_apt_bp_114_014217 crossref_primary_10_1111_jpi_12402 crossref_primary_10_1016_j_ajp_2018_03_008 crossref_primary_10_1016_j_schres_2017_10_014 crossref_primary_10_1016_j_pnpbp_2020_109941 crossref_primary_10_3111_13696998_2015_1073736 crossref_primary_10_1177_1039856217732473 crossref_primary_10_1176_appi_ps_201700536 crossref_primary_10_1007_s00213_020_05716_4 crossref_primary_10_1002_ejoc_201801090 crossref_primary_10_1002_14651858_CD014383_pub2 crossref_primary_10_1016_S2215_0366_21_00293_5 crossref_primary_10_3390_diagnostics14232745 crossref_primary_10_1017_S2045796016000305 crossref_primary_10_1177_1534650114559717 crossref_primary_10_1177_02537176211010505 crossref_primary_10_1186_s12888_017_1459_z crossref_primary_10_1212_CON_0000000000000602 crossref_primary_10_1038_s41398_021_01613_2 crossref_primary_10_7759_cureus_54927 crossref_primary_10_1016_j_psym_2018_05_011 crossref_primary_10_1192_bjp_bp_115_177261 crossref_primary_10_1016_j_pbb_2017_09_010 crossref_primary_10_1186_s12913_018_3020_2 crossref_primary_10_1038_508S18a crossref_primary_10_1007_s40664_018_0274_9 crossref_primary_10_1038_npjschz_2015_35 crossref_primary_10_1080_07391102_2022_2148748 crossref_primary_10_1080_08039488_2017_1365379 crossref_primary_10_36290_far_2022_025 crossref_primary_10_1016_j_diabet_2019_07_001 crossref_primary_10_1016_j_eurpsy_2015_09_141 crossref_primary_10_3390_biomedicines12030597 crossref_primary_10_1007_s11126_020_09841_3 crossref_primary_10_1016_j_neuroimage_2018_02_048 crossref_primary_10_1136_ebmental_2018_300003 crossref_primary_10_1002_oby_22903 crossref_primary_10_1017_neu_2015_56 crossref_primary_10_1016_j_jad_2023_04_030 crossref_primary_10_3389_fpsyt_2022_907123 crossref_primary_10_1002_bmc_5632 crossref_primary_10_1517_17425255_2015_1059821 crossref_primary_10_1111_jpm_12300 crossref_primary_10_1016_j_psyneuen_2017_11_010 crossref_primary_10_4103_0019_5545_192016 crossref_primary_10_1038_s41598_020_71014_w crossref_primary_10_1016_j_amp_2023_06_003 crossref_primary_10_1089_cap_2017_0038 crossref_primary_10_2478_cpp_2018_0023 crossref_primary_10_1007_s40258_018_0408_4 crossref_primary_10_1016_S2215_0366_18_30177_9 crossref_primary_10_1016_j_schres_2020_01_001 crossref_primary_10_1007_s00213_016_4356_0 crossref_primary_10_1080_03007995_2019_1651129 crossref_primary_10_3371_1935_1232_10_3_163 crossref_primary_10_1016_j_genhosppsych_2023_01_005 crossref_primary_10_1002_jnr_23970 crossref_primary_10_1001_jamapsychiatry_2020_4180 crossref_primary_10_1002_pds_4070 crossref_primary_10_1080_17512433_2018_1478727 crossref_primary_10_1016_S0140_6736_13_62616_1 crossref_primary_10_1080_14740338_2019_1674809 crossref_primary_10_1007_s00213_015_4024_9 crossref_primary_10_1136_bmjopen_2020_042497 crossref_primary_10_1001_jamapsychiatry_2019_3377 crossref_primary_10_1080_14740338_2024_2396396 crossref_primary_10_1186_s40360_019_0287_9 crossref_primary_10_1017_S0033291721000180 crossref_primary_10_1111_bcp_13945 crossref_primary_10_1007_s12035_018_1330_3 crossref_primary_10_1177_17446295241266897 crossref_primary_10_1002_med_21923 crossref_primary_10_1111_bcpt_12372 crossref_primary_10_1111_bdi_12860 crossref_primary_10_3389_fpsyt_2020_00543 crossref_primary_10_1002_14651858_CD001026_pub2 crossref_primary_10_1016_j_jclinepi_2021_01_015 crossref_primary_10_1177_1060028016678262 crossref_primary_10_1080_00325481_2019_1701823 crossref_primary_10_1001_jamapsychiatry_2019_3369 crossref_primary_10_1155_2020_5848601 crossref_primary_10_1016_j_neubiorev_2021_11_032 crossref_primary_10_1007_s40263_022_00923_3 crossref_primary_10_1080_13651501_2019_1576905 crossref_primary_10_1111_cts_12801 crossref_primary_10_1016_S2215_0366_15_00105_4 crossref_primary_10_1177_02698811231200020 crossref_primary_10_1007_s11126_017_9521_z crossref_primary_10_1177_2045125319881916 crossref_primary_10_3390_jcm10184095 crossref_primary_10_1038_s41386_021_01244_7 crossref_primary_10_1016_S2215_0366_14_70372_4 crossref_primary_10_1056_NEJMra1808803 crossref_primary_10_1371_journal_pone_0139403 crossref_primary_10_1002_14651858_CD012950 crossref_primary_10_1192_bjp_bp_114_154377 crossref_primary_10_1371_journal_pone_0149209 crossref_primary_10_1016_j_nsa_2022_100111 crossref_primary_10_1016_j_euroneuro_2017_07_001 crossref_primary_10_2174_1570159X16666180813155017 crossref_primary_10_1016_S0013_7006_19_30077_6 crossref_primary_10_1177_0269881119856850 crossref_primary_10_1093_ijnp_pyaa033 crossref_primary_10_3389_fpsyt_2023_1215807 crossref_primary_10_1016_j_bbi_2024_07_009 crossref_primary_10_1097_JCP_0000000000000513 crossref_primary_10_30895_2312_7821_2024_410 crossref_primary_10_1089_cap_2018_0139 crossref_primary_10_1038_s41593_021_00971_w crossref_primary_10_1517_14740338_2015_979150 crossref_primary_10_1159_000507638 crossref_primary_10_3389_fpsyt_2018_00580 crossref_primary_10_1016_j_cbpc_2025_110120 crossref_primary_10_1016_j_schres_2014_10_002 crossref_primary_10_1007_s40262_019_00793_x crossref_primary_10_1016_j_euroneuro_2015_04_014 crossref_primary_10_1007_s11886_020_01436_5 crossref_primary_10_1016_j_ejmech_2016_08_059 crossref_primary_10_1016_j_toxrep_2025_101990 crossref_primary_10_1371_journal_pone_0244944 crossref_primary_10_1097_FTD_0000000000000619 crossref_primary_10_1080_14737175_2024_2325655 crossref_primary_10_1136_eb_2015_102149 crossref_primary_10_1002_jdn_10296 crossref_primary_10_1016_j_jpsychires_2015_07_005 crossref_primary_10_1080_19315864_2018_1481474 crossref_primary_10_1016_j_bbi_2017_01_015 crossref_primary_10_1007_s11126_019_09638_z crossref_primary_10_1038_s41398_020_0722_0 crossref_primary_10_1176_appi_ajp_2013_13070984 crossref_primary_10_1517_17425255_2015_991713 crossref_primary_10_1016_j_parkreldis_2023_105356 crossref_primary_10_1080_13651501_2017_1291839 crossref_primary_10_1176_appi_ajp_2013_13070985 crossref_primary_10_1177_10600280241308287 crossref_primary_10_3389_fphar_2022_846455 crossref_primary_10_2217_pgs_16_5 crossref_primary_10_1016_j_pharep_2016_05_009 crossref_primary_10_1517_14656566_2014_947960 crossref_primary_10_25118_2763_9037_2023_v13_511 crossref_primary_10_1016_j_jpsychires_2015_07_016 crossref_primary_10_1016_j_psychres_2020_113246 crossref_primary_10_1007_s00406_018_0865_7 crossref_primary_10_1016_j_euroneuro_2019_09_204 crossref_primary_10_3389_fphar_2024_1321405 crossref_primary_10_3928_00485713_20200713_01 crossref_primary_10_3109_09638288_2015_1116622 crossref_primary_10_1007_s40263_016_0325_8 crossref_primary_10_1016_j_jep_2021_114604 crossref_primary_10_4103_ipj_ipj_269_21 crossref_primary_10_1093_schbul_sbac131 crossref_primary_10_1016_j_pnpbp_2020_109881 crossref_primary_10_3892_ol_2016_4074 crossref_primary_10_2217_cer_2018_0016 crossref_primary_10_1016_j_neubiorev_2016_10_004 crossref_primary_10_1177_0269881115626349 crossref_primary_10_1007_s40263_021_00812_1 crossref_primary_10_1007_s00406_024_01790_3 crossref_primary_10_1177_0269881115625496 crossref_primary_10_2174_1570159X23666241016090634 crossref_primary_10_1186_s12888_022_04008_9 crossref_primary_10_9740_mhc_2016_07_178 crossref_primary_10_1016_j_cell_2024_02_034 crossref_primary_10_1016_j_schres_2014_10_038 crossref_primary_10_1186_2046_4053_3_126 crossref_primary_10_1007_s40501_014_0010_9 crossref_primary_10_1089_cap_2015_0141 crossref_primary_10_1093_schizbullopen_sgac001 crossref_primary_10_1097_JCP_0000000000001800 crossref_primary_10_1017_ipm_2015_1 crossref_primary_10_1017_S1092852916000729 crossref_primary_10_1186_s12888_020_02523_1 crossref_primary_10_1177_20451253221136753 crossref_primary_10_1016_j_schres_2017_08_059 crossref_primary_10_1021_acschemneuro_8b00159 crossref_primary_10_1007_s40262_020_00969_w crossref_primary_10_1093_ijnp_pyaa004 crossref_primary_10_1007_s11428_021_00806_z crossref_primary_10_1016_j_etap_2024_104418 crossref_primary_10_1016_j_bbr_2021_113168 crossref_primary_10_1093_ijnp_pyz046 crossref_primary_10_15406_ppij_2015_02_00011 crossref_primary_10_3389_fpsyt_2014_00184 crossref_primary_10_1177_0269881117722987 crossref_primary_10_1007_s00213_019_05352_7 crossref_primary_10_1016_j_ajp_2013_11_017 crossref_primary_10_1016_j_jaac_2016_12_013 crossref_primary_10_4306_pi_2017_14_1_63 crossref_primary_10_1016_j_jphs_2018_11_004 crossref_primary_10_1177_1039856217751986 crossref_primary_10_1097_JCP_0000000000000936 crossref_primary_10_1016_j_euroneuro_2015_04_007 crossref_primary_10_1177_0269881114564096 crossref_primary_10_1016_j_psyneuen_2015_04_011 crossref_primary_10_1177_0272989X19884927 crossref_primary_10_1017_S204579601800032X crossref_primary_10_1111_acps_12982 crossref_primary_10_1016_j_schres_2022_02_015 crossref_primary_10_1177_20451253211064396 crossref_primary_10_1016_j_ecl_2020_02_010 crossref_primary_10_1016_S0140_6736_13_62246_1 crossref_primary_10_1016_S2215_0366_24_00136_6 crossref_primary_10_1177_08850666231222470 crossref_primary_10_1080_02791072_2021_1957188 crossref_primary_10_1055_a_1524_1935 crossref_primary_10_3389_fpsyt_2018_00174 crossref_primary_10_1038_s41380_024_02728_w crossref_primary_10_1080_13803395_2016_1273320 crossref_primary_10_1093_ijnp_pyz012 crossref_primary_10_1136_bmjopen_2020_039777 crossref_primary_10_1097_JCP_0000000000000595 crossref_primary_10_1097_JCP_0000000000000596 crossref_primary_10_1371_journal_pone_0124791 crossref_primary_10_1590_2237_6089_2016_0053 crossref_primary_10_1080_14728214_2020_1773792 crossref_primary_10_1136_eb_2016_102491 crossref_primary_10_1080_14656566_2022_2137403 crossref_primary_10_1016_j_encep_2021_09_004 crossref_primary_10_1177_0091217415621269 crossref_primary_10_1016_j_dsx_2024_103139 crossref_primary_10_1124_jpet_121_000979 crossref_primary_10_1007_s10304_017_0147_x crossref_primary_10_1080_17512433_2018_1549489 crossref_primary_10_1016_j_schres_2015_07_053 crossref_primary_10_1097_JCP_0000000000001450 crossref_primary_10_1039_D0OB02606A crossref_primary_10_9758_cpn_2021_19_3_434 crossref_primary_10_1016_j_diamond_2024_111533 crossref_primary_10_1097_YIC_0000000000000374 crossref_primary_10_1177_0269881116636105 crossref_primary_10_1016_j_schres_2014_12_024 crossref_primary_10_1007_s12551_021_00849_y crossref_primary_10_2174_1874220301401010001 crossref_primary_10_1017_S1092852921000249 crossref_primary_10_1016_j_bbrc_2016_10_102 crossref_primary_10_9740_mhc_2016_05_142 crossref_primary_10_1097_JCP_0000000000000573 crossref_primary_10_1097_JCP_0000000000001421 crossref_primary_10_1007_s40264_017_0543_0 crossref_primary_10_1128_spectrum_01023_23 crossref_primary_10_1016_j_euroneuro_2015_06_011 crossref_primary_10_1586_17434440_2014_911082 crossref_primary_10_1007_s00406_018_0869_3 crossref_primary_10_1111_pcn_12682 crossref_primary_10_1016_j_encep_2016_02_021 crossref_primary_10_1007_s15034_023_4505_6 crossref_primary_10_1017_S0033291724000503 crossref_primary_10_1016_j_psychres_2019_112523 crossref_primary_10_1016_j_bbr_2021_113144 crossref_primary_10_1136_eb_2014_101813 crossref_primary_10_1016_j_dhjo_2020_100988 crossref_primary_10_1097_JCP_0000000000001432 crossref_primary_10_3390_nu17030399 crossref_primary_10_1177_1049732318793418 crossref_primary_10_14412_2074_2711_2021_6_91_97 crossref_primary_10_1517_17425255_2014_908185 crossref_primary_10_3389_fpsyt_2021_656230 crossref_primary_10_4103_jfmpc_jfmpc_1439_24 crossref_primary_10_1016_j_heliyon_2023_e14199 crossref_primary_10_1097_YIC_0000000000000354 crossref_primary_10_1126_science_aaz9906 crossref_primary_10_1007_s40267_013_0074_4 crossref_primary_10_1038_s41397_021_00234_8 crossref_primary_10_1016_j_psychres_2019_112598 crossref_primary_10_1097_FTD_0000000000001089 crossref_primary_10_1097_PRA_0000000000000353 crossref_primary_10_1007_s15005_015_1530_6 crossref_primary_10_1017_S1092852920001546 crossref_primary_10_3389_fonc_2022_993367 crossref_primary_10_2217_pgs_15_133 crossref_primary_10_1176_appi_focus_20200051 crossref_primary_10_2217_pgs_15_134 crossref_primary_10_1186_s13643_023_02213_5 crossref_primary_10_1089_brain_2021_0061 crossref_primary_10_1007_s40262_019_00821_w crossref_primary_10_1016_j_schres_2019_11_017 crossref_primary_10_1016_j_drudis_2014_07_010 crossref_primary_10_1159_000477313 crossref_primary_10_3389_fpsyt_2020_00094 crossref_primary_10_1016_j_biopha_2017_05_113 crossref_primary_10_1038_s41401_020_0373_y crossref_primary_10_1016_j_schres_2024_03_033 crossref_primary_10_1016_j_schres_2018_03_017 crossref_primary_10_3389_fpsyt_2024_1383173 crossref_primary_10_1007_s15202_018_1988_4 crossref_primary_10_1097_JCP_0000000000000562 crossref_primary_10_1186_s13063_019_3198_6 crossref_primary_10_1038_nrd_2016_28 crossref_primary_10_1177_0269881116636545 crossref_primary_10_1016_j_schres_2020_12_043 crossref_primary_10_1097_PRA_0000000000000372 crossref_primary_10_1111_pcn_12654 crossref_primary_10_1086_730383 crossref_primary_10_1177_0897190019854566 crossref_primary_10_15406_ppij_2017_05_00126 crossref_primary_10_1016_j_schres_2015_07_048 crossref_primary_10_1186_s13643_021_01760_z crossref_primary_10_1155_2024_7630713 crossref_primary_10_1038_s41398_019_0519_1 crossref_primary_10_1517_17425247_2016_1115479 crossref_primary_10_1521_capn_2015_20_3_5 crossref_primary_10_1016_j_psychres_2020_112758 crossref_primary_10_1016_j_schres_2020_12_036 crossref_primary_10_1080_21548331_2020_1762366 crossref_primary_10_1089_cap_2018_0111 crossref_primary_10_1016_j_toxrep_2025_101927 crossref_primary_10_1080_17512433_2024_2310715 crossref_primary_10_1016_j_pnpbp_2024_111231 crossref_primary_10_1016_S2589_7500_20_30024_8 crossref_primary_10_1517_17460441_2014_951631 crossref_primary_10_1177_07067437241295648 crossref_primary_10_1093_ijnp_pyv060 crossref_primary_10_1016_j_ajp_2014_08_002 crossref_primary_10_3390_biomedicines11051405 crossref_primary_10_1038_s41537_020_00114_3 |
| Cites_doi | 10.1016/j.jclinepi.2008.10.001 10.1002/14651858.CD003443.pub2 10.1056/NEJMoa051688 10.1016/S0140-6736(09)60046-5 10.1176/appi.ajp.2008.08030368 10.1093/schbul/13.2.261 10.1001/archpsyc.63.10.1079 10.1016/S0140-6736(12)61729-2 10.2466/pr0.1962.10.3.799 10.1016/j.jclinepi.2005.06.006 10.1097/JCP.0b013e31828700c7 10.1002/sim.3767 10.1136/bmj.321.7273.1371 10.3109/15622975.2012.696143 10.1371/journal.pmed.1000100 10.1016/j.jclinepi.2004.02.018 10.1001/archpsyc.60.6.553 10.1136/bmj.d4909 10.1002/14651858.CD003082.pub2 10.2165/00003495-200464200-00003 10.2165/11634500-000000000-00000 10.1016/S0140-6736(11)60873-8 10.1002/sim.1875 10.1016/S0140-6736(07)60138-X 10.1002/jrsm.57 10.1111/j.1600-0447.2010.01563.x 10.1016/S0140-6736(08)61764-X 10.4088/JCP.11r07539 10.1186/1471-2288-9-2 10.1038/nrendo.2011.156 10.1007/s002130050614 10.1038/sj.mp.4002136 10.1002/jrsm.1037 10.1002/14651858.CD000284.pub2 10.4088/JCP.11r06927 10.7326/0003-4819-157-7-201210020-00525 10.1097/JCP.0b013e3181e5c14c 10.1176/appi.ajp.2009.09060802 10.1177/0962280207080643 10.2146/ajhp070261 10.1176/ajp.137.1.16 10.1002/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0 10.1016/S0140-6736(03)13306-5 10.1017/S0033291708004716 10.1016/j.jclinepi.2010.03.016 10.1016/j.schres.2005.07.025 10.1176/appi.ajp.2010.08040484 10.1002/14651858.CD001951 10.1093/schbul/sbp116 |
| ContentType | Journal Article |
| Copyright | 2013 Elsevier Ltd Elsevier Ltd 2015 INIST-CNRS Copyright © 2013 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Sep 14, 2013 |
| Copyright_xml | – notice: 2013 Elsevier Ltd – notice: Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2013 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Sep 14, 2013 |
| DBID | FBQ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 7S9 L.6 |
| DOI | 10.1016/S0140-6736(13)60733-3 |
| DatabaseName | AGRIS CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland British Nursing Database (Proquest) British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary Curriculum ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database Health & Medical Collection (Alumni) Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | Neurosciences Abstracts Neurosciences Abstracts British Nursing Index MEDLINE - Academic AGRICOLA MEDLINE ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 962 |
| ExternalDocumentID | 3070871011 23810019 27674696 10_1016_S0140_6736_13_60733_3 US201500130358 S0140673613607333 1_s2_0_S0140673613607333 |
| Genre | Meta-Analysis Comparative Study Review Journal Article |
| GeographicLocations | United States United States--US |
| GeographicLocations_xml | – name: United States – name: United States--US |
| GrantInformation | None. |
| GrantInformation_xml | – fundername: European Research Council grantid: 260559 – fundername: Medical Research Council grantid: G0700477 |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUWG ACGFS ACGOD ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGCQF AGHFR AHHHB AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ PUEGO R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU YYM Z5R ZMT .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 AEQTP FBQ NHB Y6R AAYXX ADXHL AGQPQ AGRNS AIGII CITATION 08R AALRV ABFLS ADGIM BBAFP IPNFZ IQODW PQEST PQUKI CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PRINS Q9U 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c754t-5656cb8936179676360e02b1a464f6b3a3edd63489ee1b4f6dfc96a98928f55b3 |
| IEDL.DBID | 7X7 |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Thu Jul 10 22:21:56 EDT 2025 Fri Jul 11 12:18:38 EDT 2025 Thu Jul 10 23:21:46 EDT 2025 Fri Jul 11 07:27:11 EDT 2025 Mon Jul 21 10:03:13 EDT 2025 Sat Aug 23 13:24:02 EDT 2025 Mon Jul 21 06:05:08 EDT 2025 Fri Nov 25 06:03:15 EST 2022 Tue Jul 01 03:16:12 EDT 2025 Thu Apr 24 23:00:23 EDT 2025 Wed Dec 27 19:17:55 EST 2023 Fri Feb 23 02:34:38 EST 2024 Sun Feb 23 10:18:52 EST 2025 Tue Aug 26 18:33:15 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9896 |
| Keywords | Psychosis Medicine Chemotherapy Treatment Multiple Neuroleptic Psychotropic Treatment efficiency Schizophrenia Antipsychotic Comparative study Metaanalysis |
| Language | English |
| License | CC BY 4.0 Copyright © 2013 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c754t-5656cb8936179676360e02b1a464f6b3a3edd63489ee1b4f6dfc96a98928f55b3 |
| Notes | http://dx.doi.org/10.1016/S0140-6736(13)60733-3 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 ObjectType-Review-3 content type line 23 ObjectType-Literature Review-3 |
| PMID | 23810019 |
| PQID | 1432158115 |
| PQPubID | 23462 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_1678538615 proquest_miscellaneous_1668248311 proquest_miscellaneous_1466091948 proquest_miscellaneous_1448215784 proquest_miscellaneous_1433269554 proquest_journals_1432158115 pubmed_primary_23810019 pascalfrancis_primary_27674696 crossref_citationtrail_10_1016_S0140_6736_13_60733_3 crossref_primary_10_1016_S0140_6736_13_60733_3 fao_agris_US201500130358 elsevier_sciencedirect_doi_10_1016_S0140_6736_13_60733_3 elsevier_clinicalkeyesjournals_1_s2_0_S0140673613607333 elsevier_clinicalkey_doi_10_1016_S0140_6736_13_60733_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-09-14 |
| PublicationDateYYYYMMDD | 2013-09-14 |
| PublicationDate_xml | – month: 09 year: 2013 text: 2013-09-14 day: 14 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2013 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | Gardner, Murphy, O'Donnell, Centorrino, Baldessarini (bib11) 2010; 167 Dias, Welton, Caldwell, Ades (bib33) 2010; 29 Cipriani, Barbui, Salanti (bib8) 2011; 378 Isbister, Balit, Macleod, Duffull (bib50) 2010; 30 Cipriani, Furukawa, Salanti (bib7) 2009; 373 Klein, Dieterle, Rüther, Eben, Nedopil, Hippius (bib43) 1985 Thomas, Drici, Hall (bib51) 2010; 122 Geddes, Freemantle, Harrison, Bebbington (bib4) 2000; 321 Klein, Davis (bib45) 1969 Jones, Barnes, Davies (bib56) 2006; 63 Leucht, Arbter, Engel, Kissling, Davis (bib15) 2009; 14 Davis, Chen, Glick (bib5) 2003; 60 Higgins, Green (bib24) 2011 Furukawa, Barbui, Cipriani, Brambilla, Watanabe (bib27) 2006; 59 Chouinard, Jones (bib48) 1980; 137 Strom, Eng, Faich (bib52) 2011; 168 Overall, Gorham (bib26) 1962; 10 Moreno, Sutton, Ades (bib40) 2009; 9 Lin, Chiu, Chen (bib44) 2013; 33 Trikalinos, Churchill, Ferri (bib59) 2004; 57 Hasan, Falkai, Wobrock (bib13) 2012; 13 Salanti, Marinho, Higgins (bib34) 2009; 62 CD006369. Cohen (bib42) 1988 Khin, Chen, Yang, Yang, Laughren (bib36) 2012; 73 bib2 Wu TX, Li YP, Liu GJ, et al. Investigation of authenticity of ‘claimed’ randomized controlled trials (RCTs) and quality assessment of RCT reports published in China. XIV Cochrane Colloquium; Dublin; Oct 23–26, 2006. Salanti, Higgins, Ades, Ioannides (bib29) 2008; 17 Donnelly, Waraich, Adams (bib37) 2002; 2 Hartling, Abou-Setta, Dursun, Mousavi, Pasichnyk, Newton (bib21) 2012; 157 Leucht, Corves, Arbter, Engel, Li, Davis (bib3) 2009; 373 Vos, Flaxman, Naghavi (bib1) 2012; 380 Leucht C, Kitzmantel M, Chua L, Kane J, Leucht S. Haloperidol versus chlorpromazine for schizophrenia. Salanti (bib32) 2012; 3 Glick, Correll, Altamura (bib60) 2011; 72 De Hert, Yu, Detraux, Sweers, van Winkel, Correll (bib22) 2012; 26 Leucht, Wahlbeck, Hamann, Kissling (bib38) 2003; 361 Lieberman, Stroup, McEvoy (bib55) 2005; 353 Irving, Adams, Lawrie (bib18) 2006; 4 Pappa, Dazzan (bib49) 2009; 39 De Hert, Detraux, van Winkel, Yu, Correll (bib58) 2012; 8 Wetzel, Grunder, Hillert (bib54) 1998; 137 Nussbaum A, Stroup TS. Paliperidone for schizophrenia. Adams, Awad, Rathbone, Thornley (bib19) 2007; 2 (bib14) 2009 Lu, Ades (bib28) 2004; 23 Tandon, Fleischhacker (bib35) 2005; 79 Liberati, Altman, Tetzlaff (bib41) 2009; 6 Salanti, Ades, Ioannides (bib31) 2011; 64 Higgins, Whitehead (bib30) 1996; 15 Leucht, Komossa, Rummel-Kluge (bib47) 2009; 166 Haddad, Wieck (bib53) 2004; 64 CD004278. bib20 Hartung, Wada, Laux, Leucht (bib57) 2005; 1 Caldwell, Gibb, Ades (bib9) 2007; 369 Buchanan, Kreyenbuhl, Kelly (bib12) 2010; 36 Kay, Fiszbein (bib25) 1987; 13 Dolder, Nelson, Deyo (bib46) 2008; 65 Chaimani, Salanti (bib39) 2012; 3 Song, Xiong, Parekh-Bhurke (bib10) 2011; 343 Leucht, Komossa, Rummel-Kluge (bib6) 2009; 166 Leucht (10.1016/S0140-6736(13)60733-3_bib47) 2009; 166 Lin (10.1016/S0140-6736(13)60733-3_bib44) 2013; 33 Leucht (10.1016/S0140-6736(13)60733-3_bib3) 2009; 373 Cipriani (10.1016/S0140-6736(13)60733-3_bib8) 2011; 378 Leucht (10.1016/S0140-6736(13)60733-3_bib15) 2009; 14 Higgins (10.1016/S0140-6736(13)60733-3_bib24) 2011 10.1016/S0140-6736(13)60733-3_bib16 Isbister (10.1016/S0140-6736(13)60733-3_bib50) 2010; 30 10.1016/S0140-6736(13)60733-3_bib17 Chaimani (10.1016/S0140-6736(13)60733-3_bib39) 2012; 3 Higgins (10.1016/S0140-6736(13)60733-3_bib30) 1996; 15 De Hert (10.1016/S0140-6736(13)60733-3_bib58) 2012; 8 Vos (10.1016/S0140-6736(13)60733-3_bib1) 2012; 380 Kay (10.1016/S0140-6736(13)60733-3_bib25) 1987; 13 Furukawa (10.1016/S0140-6736(13)60733-3_bib27) 2006; 59 De Hert (10.1016/S0140-6736(13)60733-3_bib22) 2012; 26 Tandon (10.1016/S0140-6736(13)60733-3_bib35) 2005; 79 Irving (10.1016/S0140-6736(13)60733-3_bib18) 2006; 4 Overall (10.1016/S0140-6736(13)60733-3_bib26) 1962; 10 Adams (10.1016/S0140-6736(13)60733-3_bib19) 2007; 2 Liberati (10.1016/S0140-6736(13)60733-3_bib41) 2009; 6 Wetzel (10.1016/S0140-6736(13)60733-3_bib54) 1998; 137 Davis (10.1016/S0140-6736(13)60733-3_bib5) 2003; 60 Lieberman (10.1016/S0140-6736(13)60733-3_bib55) 2005; 353 Strom (10.1016/S0140-6736(13)60733-3_bib52) 2011; 168 Thomas (10.1016/S0140-6736(13)60733-3_bib51) 2010; 122 Hartling (10.1016/S0140-6736(13)60733-3_bib21) 2012; 157 Klein (10.1016/S0140-6736(13)60733-3_bib45) 1969 Glick (10.1016/S0140-6736(13)60733-3_bib60) 2011; 72 Salanti (10.1016/S0140-6736(13)60733-3_bib29) 2008; 17 Cipriani (10.1016/S0140-6736(13)60733-3_bib7) 2009; 373 Pappa (10.1016/S0140-6736(13)60733-3_bib49) 2009; 39 Klein (10.1016/S0140-6736(13)60733-3_bib43) 1985 Khin (10.1016/S0140-6736(13)60733-3_bib36) 2012; 73 Leucht (10.1016/S0140-6736(13)60733-3_bib38) 2003; 361 Geddes (10.1016/S0140-6736(13)60733-3_bib4) 2000; 321 Hasan (10.1016/S0140-6736(13)60733-3_bib13) 2012; 13 Leucht (10.1016/S0140-6736(13)60733-3_bib6) 2009; 166 Moreno (10.1016/S0140-6736(13)60733-3_bib40) 2009; 9 Cohen (10.1016/S0140-6736(13)60733-3_bib42) 1988 Trikalinos (10.1016/S0140-6736(13)60733-3_bib59) 2004; 57 Hartung (10.1016/S0140-6736(13)60733-3_bib57) 2005; 1 Buchanan (10.1016/S0140-6736(13)60733-3_bib12) 2010; 36 Salanti (10.1016/S0140-6736(13)60733-3_bib32) 2012; 3 Gardner (10.1016/S0140-6736(13)60733-3_bib11) 2010; 167 10.1016/S0140-6736(13)60733-3_bib23 Caldwell (10.1016/S0140-6736(13)60733-3_bib9) 2007; 369 Dias (10.1016/S0140-6736(13)60733-3_bib33) 2010; 29 Donnelly (10.1016/S0140-6736(13)60733-3_bib37) 2002; 2 Dolder (10.1016/S0140-6736(13)60733-3_bib46) 2008; 65 Salanti (10.1016/S0140-6736(13)60733-3_bib31) 2011; 64 Lu (10.1016/S0140-6736(13)60733-3_bib28) 2004; 23 Chouinard (10.1016/S0140-6736(13)60733-3_bib48) 1980; 137 Salanti (10.1016/S0140-6736(13)60733-3_bib34) 2009; 62 Song (10.1016/S0140-6736(13)60733-3_bib10) 2011; 343 Jones (10.1016/S0140-6736(13)60733-3_bib56) 2006; 63 Haddad (10.1016/S0140-6736(13)60733-3_bib53) 2004; 64 (10.1016/S0140-6736(13)60733-3_bib14) 2009 24247697 - Ann Intern Med. 2013 Nov 19;159(10):JC7. doi: 10.7326/0003-4819-159-10-201311190-02007. Lancet. 2013 Sep 14;382(9896):940 24344173 - Evid Based Ment Health. 2014 Feb;17(1):9. doi: 10.1136/eb-2013-101612. 24315170 - Lancet. 2013 Dec 7;382(9908):1874-5. doi: 10.1016/S0140-6736(13)62617-3. 24315168 - Lancet. 2013 Dec 7;382(9908):1873-4. doi: 10.1016/S0140-6736(13)62615-X. 23810018 - Lancet. 2013 Sep 14;382(9896):919-20. doi: 10.1016/S0140-6736(13)61032-6. 34537097 - Lancet Psychiatry. 2021 Oct;8(10):863. doi: 10.1016/S2215-0366(21)00361-8. 24315169 - Lancet. 2013 Dec 7;382(9908):1874. doi: 10.1016/S0140-6736(13)62616-1. |
| References_xml | – volume: 60 start-page: 553 year: 2003 end-page: 564 ident: bib5 article-title: A meta-analysis of the efficacy of second-generation antipsychotics publication-title: Arch Gen Psychiatry – volume: 373 start-page: 31 year: 2009 end-page: 41 ident: bib3 article-title: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis publication-title: Lancet – reference: Nussbaum A, Stroup TS. Paliperidone for schizophrenia. – reference: : CD006369. – volume: 2 year: 2007 ident: bib19 article-title: Chlorpromazine versus placebo for schizophrenia publication-title: Cochrane Database Syst Rev – volume: 15 start-page: 2733 year: 1996 end-page: 2749 ident: bib30 article-title: Borrowing strength from external trials in a meta-analysis publication-title: Stat Med – volume: 29 start-page: 932 year: 2010 end-page: 944 ident: bib33 article-title: Checking consistency in mixed treatment comparison meta-analysis publication-title: Stat Med – volume: 64 start-page: 229 year: 2004 end-page: 314 ident: bib53 article-title: Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management publication-title: Drugs – volume: 2 year: 2002 ident: bib37 article-title: Haloperidol dose for the acute phase of schizophrenia publication-title: Cochrane Database Syst Rev – volume: 59 start-page: 7 year: 2006 end-page: 10 ident: bib27 article-title: Imputing missing standard deviations in meta-analyses can provide accurate results publication-title: J Clin Epidemiol – volume: 137 start-page: 223 year: 1998 end-page: 232 ident: bib54 article-title: Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology—a double-blind controlled study comparing a selective D-2-like antagonist to a mixed D-1-/D- 2-like antagonist publication-title: Psychopharmacology (Berl) – volume: 3 start-page: 80 year: 2012 end-page: 97 ident: bib32 article-title: Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool publication-title: Res Synth Methods – year: 2009 ident: bib14 publication-title: Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update) – volume: 353 start-page: 1209 year: 2005 end-page: 1223 ident: bib55 article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia publication-title: N Engl J Med – year: 1969 ident: bib45 publication-title: Diagnosis and drug treatment of psychiatric disorders – volume: 14 start-page: 429 year: 2009 end-page: 447 ident: bib15 article-title: How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials publication-title: Mol Psychiatry – volume: 361 start-page: 1581 year: 2003 end-page: 1589 ident: bib38 article-title: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis publication-title: Lancet – ident: bib20 article-title: Cochrane Schizophrenia Group Specialised Register – volume: 30 start-page: 391 year: 2010 end-page: 395 ident: bib50 article-title: Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes publication-title: J Clin Psychopharmacol – volume: 63 start-page: 1079 year: 2006 end-page: 1086 ident: bib56 article-title: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia—cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1) publication-title: Arch Gen Psychiatry – volume: 72 start-page: 1616 year: 2011 end-page: 1627 ident: bib60 article-title: Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach publication-title: J Clin Psychiatry – volume: 62 start-page: 857 year: 2009 end-page: 864 ident: bib34 article-title: A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered publication-title: J Clin Epidemiol – volume: 167 start-page: 686 year: 2010 end-page: 693 ident: bib11 article-title: International consensus study of antipsychotic dosing publication-title: Am J Psychiatry – volume: 17 start-page: 279 year: 2008 end-page: 301 ident: bib29 article-title: Evaluation of networks of randomized trials publication-title: Stat Methods Med Res – volume: 4 year: 2006 ident: bib18 article-title: Haloperidol versus placebo for schizophrenia publication-title: Cochrane Database of Syst Rev – volume: 10 start-page: 790 year: 1962 end-page: 812 ident: bib26 article-title: The Brief Psychiatric Rating Scale publication-title: Psychol Rep – volume: 13 start-page: 318 year: 2012 end-page: 378 ident: bib13 article-title: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance publication-title: World J Biol Psychiatry – volume: 137 start-page: 16 year: 1980 end-page: 21 ident: bib48 article-title: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics publication-title: Am J Psychiatry – volume: 13 start-page: 261 year: 1987 end-page: 275 ident: bib25 article-title: The positive and negative symptome scale (PANSS) for schizophrenia publication-title: Schizophr Bull – volume: 166 start-page: 152 year: 2009 end-page: 163 ident: bib6 article-title: A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia publication-title: Am J Psychiatry – start-page: 687 year: 1985 end-page: 691 ident: bib43 article-title: A double-blind comparison of amisulpride vs. haloperidol in acute schizophrenic patients publication-title: Psychiatry, the state of the art – reference: Wu TX, Li YP, Liu GJ, et al. Investigation of authenticity of ‘claimed’ randomized controlled trials (RCTs) and quality assessment of RCT reports published in China. XIV Cochrane Colloquium; Dublin; Oct 23–26, 2006. – ident: bib2 article-title: Antipsychotic drugs: technologies and global markets – volume: 373 start-page: 746 year: 2009 end-page: 758 ident: bib7 article-title: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis publication-title: Lancet – year: 1988 ident: bib42 publication-title: Statistical power analysis for the behavioral sciences – volume: 1 year: 2005 ident: bib57 article-title: Perphenazine for schizophrenia publication-title: Cochrane Database Syst Rev – volume: 343 start-page: d4909 year: 2011 ident: bib10 article-title: Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study publication-title: BMJ – volume: 168 start-page: 193 year: 2011 end-page: 201 ident: bib52 article-title: Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18 154 patients with schizophrenia: the ziprasidone observational study of cardiac outcomes (ZODIAC) publication-title: Am J Psychiatry – volume: 64 start-page: 163 year: 2011 end-page: 171 ident: bib31 article-title: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial publication-title: J Clin Epidemiol – volume: 73 start-page: 856 year: 2012 end-page: 864 ident: bib36 article-title: Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration publication-title: J Clin Psychiatry – volume: 9 start-page: 2 year: 2009 ident: bib40 article-title: Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study publication-title: BMC Med Res Methodol – volume: 23 start-page: 3105 year: 2004 end-page: 3124 ident: bib28 article-title: Combination of direct and indirect evidence in mixed treatment comparisons publication-title: Stat Med – volume: 36 start-page: 71 year: 2010 end-page: 93 ident: bib12 article-title: The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements publication-title: Schizophr Bull – volume: 65 start-page: 403 year: 2008 end-page: 413 ident: bib46 article-title: Paliperidone for schizophrenia publication-title: Am J Health Syst Pharm – reference: : CD004278. – volume: 6 start-page: e1000100 year: 2009 ident: bib41 article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration publication-title: PLoS Med – volume: 26 start-page: 733 year: 2012 end-page: 759 ident: bib22 article-title: Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis publication-title: CNS Drugs – volume: 57 start-page: 1124 year: 2004 end-page: 1130 ident: bib59 article-title: Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time publication-title: J Clin Epidemiol – volume: 3 start-page: 161 year: 2012 end-page: 176 ident: bib39 article-title: Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions publication-title: Res Synth Methods – volume: 369 start-page: 270 year: 2007 ident: bib9 article-title: Validity of indirect comparisons in meta-analysis publication-title: Lancet – volume: 122 start-page: 345 year: 2010 end-page: 355 ident: bib51 article-title: Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP) publication-title: Acta Psychiatr Scand – year: 2011 ident: bib24 publication-title: Cochrane handbook for systematic reviews of interventions, version 5.1.0 – volume: 321 start-page: 1371 year: 2000 end-page: 1376 ident: bib4 article-title: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis publication-title: BMJ – volume: 378 start-page: 1306 year: 2011 end-page: 1315 ident: bib8 article-title: Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis publication-title: Lancet – reference: Leucht C, Kitzmantel M, Chua L, Kane J, Leucht S. Haloperidol versus chlorpromazine for schizophrenia. – volume: 33 start-page: 211 year: 2013 end-page: 214 ident: bib44 article-title: Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study publication-title: J Clin Psychopharmacol – volume: 8 start-page: 114 year: 2012 end-page: 126 ident: bib58 article-title: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs publication-title: Nat Rev Endocrinol – volume: 166 start-page: 152 year: 2009 end-page: 163 ident: bib47 article-title: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia publication-title: Am J Psychiatry – volume: 39 start-page: 1065 year: 2009 end-page: 1076 ident: bib49 article-title: Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review publication-title: Psychol Med – volume: 380 start-page: 2163 year: 2012 end-page: 2196 ident: bib1 article-title: Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 publication-title: Lancet – volume: 157 start-page: 498 year: 2012 end-page: 511 ident: bib21 article-title: Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis publication-title: Ann Intern Med – volume: 79 start-page: 145 year: 2005 end-page: 155 ident: bib35 article-title: Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment publication-title: Schizophr Res – volume: 62 start-page: 857 year: 2009 ident: 10.1016/S0140-6736(13)60733-3_bib34 article-title: A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2008.10.001 – volume: 1 year: 2005 ident: 10.1016/S0140-6736(13)60733-3_bib57 article-title: Perphenazine for schizophrenia publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD003443.pub2 – volume: 353 start-page: 1209 year: 2005 ident: 10.1016/S0140-6736(13)60733-3_bib55 article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia publication-title: N Engl J Med doi: 10.1056/NEJMoa051688 – volume: 373 start-page: 746 year: 2009 ident: 10.1016/S0140-6736(13)60733-3_bib7 article-title: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(09)60046-5 – volume: 166 start-page: 152 year: 2009 ident: 10.1016/S0140-6736(13)60733-3_bib47 article-title: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2008.08030368 – volume: 13 start-page: 261 year: 1987 ident: 10.1016/S0140-6736(13)60733-3_bib25 article-title: The positive and negative symptome scale (PANSS) for schizophrenia publication-title: Schizophr Bull doi: 10.1093/schbul/13.2.261 – volume: 63 start-page: 1079 year: 2006 ident: 10.1016/S0140-6736(13)60733-3_bib56 article-title: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia—cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1) publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.63.10.1079 – volume: 380 start-page: 2163 year: 2012 ident: 10.1016/S0140-6736(13)60733-3_bib1 article-title: Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 publication-title: Lancet doi: 10.1016/S0140-6736(12)61729-2 – year: 1969 ident: 10.1016/S0140-6736(13)60733-3_bib45 – volume: 10 start-page: 790 year: 1962 ident: 10.1016/S0140-6736(13)60733-3_bib26 article-title: The Brief Psychiatric Rating Scale publication-title: Psychol Rep doi: 10.2466/pr0.1962.10.3.799 – ident: 10.1016/S0140-6736(13)60733-3_bib16 – volume: 59 start-page: 7 year: 2006 ident: 10.1016/S0140-6736(13)60733-3_bib27 article-title: Imputing missing standard deviations in meta-analyses can provide accurate results publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2005.06.006 – year: 2009 ident: 10.1016/S0140-6736(13)60733-3_bib14 – volume: 33 start-page: 211 year: 2013 ident: 10.1016/S0140-6736(13)60733-3_bib44 article-title: Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study publication-title: J Clin Psychopharmacol doi: 10.1097/JCP.0b013e31828700c7 – volume: 29 start-page: 932 year: 2010 ident: 10.1016/S0140-6736(13)60733-3_bib33 article-title: Checking consistency in mixed treatment comparison meta-analysis publication-title: Stat Med doi: 10.1002/sim.3767 – volume: 321 start-page: 1371 year: 2000 ident: 10.1016/S0140-6736(13)60733-3_bib4 article-title: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis publication-title: BMJ doi: 10.1136/bmj.321.7273.1371 – volume: 13 start-page: 318 year: 2012 ident: 10.1016/S0140-6736(13)60733-3_bib13 article-title: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance publication-title: World J Biol Psychiatry doi: 10.3109/15622975.2012.696143 – volume: 6 start-page: e1000100 year: 2009 ident: 10.1016/S0140-6736(13)60733-3_bib41 article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration publication-title: PLoS Med doi: 10.1371/journal.pmed.1000100 – volume: 57 start-page: 1124 year: 2004 ident: 10.1016/S0140-6736(13)60733-3_bib59 article-title: Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2004.02.018 – volume: 60 start-page: 553 year: 2003 ident: 10.1016/S0140-6736(13)60733-3_bib5 article-title: A meta-analysis of the efficacy of second-generation antipsychotics publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.60.6.553 – volume: 343 start-page: d4909 year: 2011 ident: 10.1016/S0140-6736(13)60733-3_bib10 article-title: Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study publication-title: BMJ doi: 10.1136/bmj.d4909 – volume: 4 year: 2006 ident: 10.1016/S0140-6736(13)60733-3_bib18 article-title: Haloperidol versus placebo for schizophrenia publication-title: Cochrane Database of Syst Rev doi: 10.1002/14651858.CD003082.pub2 – volume: 64 start-page: 229 year: 2004 ident: 10.1016/S0140-6736(13)60733-3_bib53 article-title: Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management publication-title: Drugs doi: 10.2165/00003495-200464200-00003 – volume: 26 start-page: 733 year: 2012 ident: 10.1016/S0140-6736(13)60733-3_bib22 article-title: Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis publication-title: CNS Drugs doi: 10.2165/11634500-000000000-00000 – volume: 166 start-page: 152 year: 2009 ident: 10.1016/S0140-6736(13)60733-3_bib6 article-title: A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2008.08030368 – volume: 378 start-page: 1306 year: 2011 ident: 10.1016/S0140-6736(13)60733-3_bib8 article-title: Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(11)60873-8 – volume: 23 start-page: 3105 year: 2004 ident: 10.1016/S0140-6736(13)60733-3_bib28 article-title: Combination of direct and indirect evidence in mixed treatment comparisons publication-title: Stat Med doi: 10.1002/sim.1875 – volume: 369 start-page: 270 year: 2007 ident: 10.1016/S0140-6736(13)60733-3_bib9 article-title: Validity of indirect comparisons in meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(07)60138-X – volume: 3 start-page: 161 year: 2012 ident: 10.1016/S0140-6736(13)60733-3_bib39 article-title: Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions publication-title: Res Synth Methods doi: 10.1002/jrsm.57 – volume: 122 start-page: 345 year: 2010 ident: 10.1016/S0140-6736(13)60733-3_bib51 article-title: Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP) publication-title: Acta Psychiatr Scand doi: 10.1111/j.1600-0447.2010.01563.x – volume: 373 start-page: 31 year: 2009 ident: 10.1016/S0140-6736(13)60733-3_bib3 article-title: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(08)61764-X – year: 2011 ident: 10.1016/S0140-6736(13)60733-3_bib24 – volume: 73 start-page: 856 year: 2012 ident: 10.1016/S0140-6736(13)60733-3_bib36 article-title: Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration publication-title: J Clin Psychiatry doi: 10.4088/JCP.11r07539 – volume: 9 start-page: 2 year: 2009 ident: 10.1016/S0140-6736(13)60733-3_bib40 article-title: Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study publication-title: BMC Med Res Methodol doi: 10.1186/1471-2288-9-2 – year: 1988 ident: 10.1016/S0140-6736(13)60733-3_bib42 – volume: 8 start-page: 114 year: 2012 ident: 10.1016/S0140-6736(13)60733-3_bib58 article-title: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2011.156 – start-page: 687 year: 1985 ident: 10.1016/S0140-6736(13)60733-3_bib43 article-title: A double-blind comparison of amisulpride vs. haloperidol in acute schizophrenic patients – volume: 137 start-page: 223 year: 1998 ident: 10.1016/S0140-6736(13)60733-3_bib54 article-title: Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology—a double-blind controlled study comparing a selective D-2-like antagonist to a mixed D-1-/D- 2-like antagonist publication-title: Psychopharmacology (Berl) doi: 10.1007/s002130050614 – volume: 14 start-page: 429 year: 2009 ident: 10.1016/S0140-6736(13)60733-3_bib15 article-title: How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4002136 – volume: 3 start-page: 80 year: 2012 ident: 10.1016/S0140-6736(13)60733-3_bib32 article-title: Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool publication-title: Res Synth Methods doi: 10.1002/jrsm.1037 – volume: 2 year: 2007 ident: 10.1016/S0140-6736(13)60733-3_bib19 article-title: Chlorpromazine versus placebo for schizophrenia publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD000284.pub2 – volume: 72 start-page: 1616 year: 2011 ident: 10.1016/S0140-6736(13)60733-3_bib60 article-title: Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach publication-title: J Clin Psychiatry doi: 10.4088/JCP.11r06927 – volume: 157 start-page: 498 year: 2012 ident: 10.1016/S0140-6736(13)60733-3_bib21 article-title: Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis publication-title: Ann Intern Med doi: 10.7326/0003-4819-157-7-201210020-00525 – ident: 10.1016/S0140-6736(13)60733-3_bib23 – volume: 30 start-page: 391 year: 2010 ident: 10.1016/S0140-6736(13)60733-3_bib50 article-title: Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes publication-title: J Clin Psychopharmacol doi: 10.1097/JCP.0b013e3181e5c14c – volume: 167 start-page: 686 year: 2010 ident: 10.1016/S0140-6736(13)60733-3_bib11 article-title: International consensus study of antipsychotic dosing publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2009.09060802 – volume: 17 start-page: 279 year: 2008 ident: 10.1016/S0140-6736(13)60733-3_bib29 article-title: Evaluation of networks of randomized trials publication-title: Stat Methods Med Res doi: 10.1177/0962280207080643 – ident: 10.1016/S0140-6736(13)60733-3_bib17 – volume: 65 start-page: 403 year: 2008 ident: 10.1016/S0140-6736(13)60733-3_bib46 article-title: Paliperidone for schizophrenia publication-title: Am J Health Syst Pharm doi: 10.2146/ajhp070261 – volume: 137 start-page: 16 year: 1980 ident: 10.1016/S0140-6736(13)60733-3_bib48 article-title: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics publication-title: Am J Psychiatry doi: 10.1176/ajp.137.1.16 – volume: 15 start-page: 2733 year: 1996 ident: 10.1016/S0140-6736(13)60733-3_bib30 article-title: Borrowing strength from external trials in a meta-analysis publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0 – volume: 361 start-page: 1581 year: 2003 ident: 10.1016/S0140-6736(13)60733-3_bib38 article-title: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(03)13306-5 – volume: 39 start-page: 1065 year: 2009 ident: 10.1016/S0140-6736(13)60733-3_bib49 article-title: Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review publication-title: Psychol Med doi: 10.1017/S0033291708004716 – volume: 64 start-page: 163 year: 2011 ident: 10.1016/S0140-6736(13)60733-3_bib31 article-title: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2010.03.016 – volume: 79 start-page: 145 year: 2005 ident: 10.1016/S0140-6736(13)60733-3_bib35 article-title: Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment publication-title: Schizophr Res doi: 10.1016/j.schres.2005.07.025 – volume: 168 start-page: 193 year: 2011 ident: 10.1016/S0140-6736(13)60733-3_bib52 article-title: Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18 154 patients with schizophrenia: the ziprasidone observational study of cardiac outcomes (ZODIAC) publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2010.08040484 – volume: 2 year: 2002 ident: 10.1016/S0140-6736(13)60733-3_bib37 article-title: Haloperidol dose for the acute phase of schizophrenia publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD001951 – volume: 36 start-page: 71 year: 2010 ident: 10.1016/S0140-6736(13)60733-3_bib12 article-title: The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements publication-title: Schizophr Bull doi: 10.1093/schbul/sbp116 – reference: 24315168 - Lancet. 2013 Dec 7;382(9908):1873-4. doi: 10.1016/S0140-6736(13)62615-X. – reference: 34537097 - Lancet Psychiatry. 2021 Oct;8(10):863. doi: 10.1016/S2215-0366(21)00361-8. – reference: 24315169 - Lancet. 2013 Dec 7;382(9908):1874. doi: 10.1016/S0140-6736(13)62616-1. – reference: - Lancet. 2013 Sep 14;382(9896):940 – reference: 23810018 - Lancet. 2013 Sep 14;382(9896):919-20. doi: 10.1016/S0140-6736(13)61032-6. – reference: 24247697 - Ann Intern Med. 2013 Nov 19;159(10):JC7. doi: 10.7326/0003-4819-159-10-201311190-02007. – reference: 24315170 - Lancet. 2013 Dec 7;382(9908):1874-5. doi: 10.1016/S0140-6736(13)62617-3. – reference: 24344173 - Evid Based Ment Health. 2014 Feb;17(1):9. doi: 10.1136/eb-2013-101612. |
| SSID | ssj0004605 |
| Score | 2.6434107 |
| SecondaryResourceType | review_article |
| Snippet | The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses... Summary Background The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise... BACKGROUND: The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise... Background The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise... Background: The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise... |
| SourceID | proquest pubmed pascalfrancis crossref fao elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 951 |
| SubjectTerms | Adult Adult and adolescent clinical studies adverse effects Antipsychotic Agents - therapeutic use Antipsychotics Bias Biological and medical sciences chlorpromazine Drug dosages Food and Drug Administration General aspects guidelines haloperidol Health policy Humans Internal Medicine Internet Medical research Medical sciences Mental disorders mental health Meta-analysis Neuropharmacology odds ratio patients Pharmaceutical industry Pharmacology. Drug treatments prolactin Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses Psychotropic drugs randomized clinical trials Randomized Controlled Trials as Topic risk Schizophrenia Schizophrenia - drug therapy sedation Sensitivity analysis Side effects Statistical analysis Studies Systematic review Treatment Outcome United States weight gain |
| Title | Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673613607333 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673613607333 https://dx.doi.org/10.1016/S0140-6736(13)60733-3 https://www.ncbi.nlm.nih.gov/pubmed/23810019 https://www.proquest.com/docview/1432158115 https://www.proquest.com/docview/1433269554 https://www.proquest.com/docview/1448215784 https://www.proquest.com/docview/1466091948 https://www.proquest.com/docview/1668248311 https://www.proquest.com/docview/1678538615 |
| Volume | 382 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Pb9MwFLbYJiEuiN_rGJWROMDBrI4dx-aCoNo0IW1CjEq9WXbsTJW2ZDTpYf_9nhMnBanruPTgvpfEsf3eF_u97yH0wYDJS1Mb0n6LCeG5osRa5UjhUgPo2JhMhQTns3NxOuM_5uk8brjVMayyt4mtoXZVHvbIj8Cvg3eSAGC-3vwhoWpUOF2NJTR20F6gLguzOptnm_Ii2xD3dQbP0cXQ-JGyTyKULiTsPt-0U5gqBE2aGt5b0RW8uB-Rtp7p5Bl6GiEl_tbNgefokS9foMdn8dD8JVpN1wzf2AfKCJPfYlM63FRXftkRdd_iqsA0heZmETOzFjl2y9VljRclrv-OzfuCDe4DEckQqV7ja98YYiLLySs0Ozn-PT0lsdoCybOUNyQgu9wCfAFMo0QWeMT8JLHUcMELYZlh3jnBuFTeUwtNrsiVMEoqGGYYbvYa7ZZV6fcRtnYCsDJxjgnBHbMK3KClExu4xqgs3Ajx_j3rPFKRh4oYV3pDzBlluh0ezUbo86B203FxPKQg-kHUfaIpmEYN3uIhxWyToq_jAq811XWiJ512UKasVQVNOWhGDNNhk_-56T7MM20uwbrr2UUS9qLCuTJL5QiN_5l8Q_eTwMUklBihw3426vUzDktmhN4Pf4P5CGdCpvTVqpUBAK8AVG6T4RIulMmtMkIA9FRcbpERQiZcMkq3yWQAIKUIz_ymW1XrzgY2OvgkOdje2bfoSdLWLFGE8kO02yxX_h0gx8aOW_MAv3JKx2jv-_H5z193PPxk6Q |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbaIgEXxLsLpRgJJDiExrHj2EgIoYVqS7u9tCv1ZuzYqVYqSdlkhfZP8RsZ57UgbbdcenU8SSYznvkczwOh1xpMXhwbn_abhQFLJQmMkTbIbKwBHWudSJ_gPD7mown7dhafbaDfXS6MD6vsbGJtqG2R-n_ke-DXwTsJADCfLn8GvmuUP13tWmg0anHoFr9gy1Z-PPgC8n0TRftfT4ejoO0qEKRJzKrAI5jUgJsG3y154utluTAyRDPOMm6ops5aTpmQzhEDQzZLJddSSGAH2KJw3010i1FYmj4zfUhW5WHWIfXLjKG9k37wLaHvuG-VGNCrfOFmpgsfpKlLkFPWNNi4GgHXnnD_PrrXQlj8udG5B2jD5Q_R7XF7SP8IzYfLiuLY-RIVOl1gnVtcFRdu1hQGX-AiwySG4WraZoJNU2xn8_MST3Nc_h0L-AFr3AU-Bn1kfIl_uEoHuq2q8hhNbkQOT9BWXuRuG2FjQoCxkbWUc2apkeB2DQmNr21GRGYHiHXfWaVt6XPfgeNCrYhxI1TV4lF0gN73ZJdN7Y_rCHgnRNUltoIpVuCdriNMVhG6sjUopSKqjFTYUHtiQmtSoBQ9ZYuZGiz0Pw_dBj1T-hy8iZqcRP7flz_HprEYoN1_lK9nP_K1n7jkA7TTaaNavmO_RAfoVX8ZzJU_g9K5K-b1HNgwSACx6-YwATdKxNo5nAPUlUysmcO5iJighKybkwBgFdy_89NmVS2Z9dXvYAv0bD2zL9Gd0en4SB0dHB8-R3ejul-KDAjbQVvVbO5eAGqtzG5tKjD6ftO26Q9DsZ4p |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe2IU28IL5XGMNIIMFDaBw7jo2EEOqoNsYmpFFpb8aOnanSSEaTCvVf46_jnK-C1HW87NXxJbnc-e7n-D4QeqnB5MWx8Wm_WRiwVJLAGGmDzMYa0LHWifQJzscn_GDCPp_FZxvod5cL48MqO5tYG2pbpP4f-RD8OngnAQBmmLVhEV_3xx8ufwa-g5Q_ae3aaTQqcuQWv2D7Vr4_3AdZv4qi8advo4Og7TAQpEnMqsCjmdSAywY_Lnnia2e5MDJEM84ybqimzlpOmZDOEQNDNksl11JIYA1YpHDfTXQroYnwa0yMyKqczDq8fpk9NDztB18T-ob7tokBvcovbma68AGbugSZZU2zjavRcO0Vx3fRnRbO4o-N_t1DGy6_j7aP2wP7B2g-WlYXx86Xq9DpAuvc4qq4cLOmSPgCFxkmMQxX0zYrbJpiO5ufl3ia4_LvuMB3WOMuCDLoo-RL_MNVOtBthZWHaHIjcniEtvIidzsIGxMCpI2spZwzS40EF2xIaHydMyIyO0Cs-84qbcug-24cF2pFvBuhqhaPogP0tie7bOqAXEfAOyGqLskVzLICT3UdYbKK0JWtcSkVUWWkwobaExNakwKl6Clb_NTgov956A7omdLn4FnU5DTy_8H8mTaNxQDt_aN8PfuRrwPFJR-g3U4b1fId--U6QC_6y2C6_HmUzl0xr-fA5kECoF03hwm4USLWzuEcYK9kYs0czkXEBCVk3ZwEwKvg_p0fN6tqyayvhAfboSfrmX2OtsEqqS-HJ0dP0e2obp0iA8J20VY1m7tnAGArs1dbCoy-37Rp-gNnlaJf |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparative+efficacy+and+tolerability+of+15+antipsychotic+drugs+in+schizophrenia%3A+a+multiple-treatments+meta-analysis&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Leucht%2C+Stefan&rft.au=Cipriani%2C+Andrea&rft.au=Spineli%2C+Loukia&rft.au=Mavridis%2C+Dimitris&rft.date=2013-09-14&rft.issn=0140-6736&rft.volume=382&rft.issue=9896+p.951-962&rft.spage=951&rft.epage=962&rft_id=info:doi/10.1016%2FS0140-6736%2813%2960733-3&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673613X6043X%2Fcov150h.gif |